<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Midazolam: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Midazolam: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Midazolam: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10858" href="/d/html/10858.html" rel="external">see "Midazolam: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12611" href="/d/html/12611.html" rel="external">see "Midazolam: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709086"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Respiratory depression and personnel/equipment for monitoring and resuscitation (injection, oral):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Midazolam has been associated with profound sedation, respiratory depression, and respiratory arrest, especially when used for sedation in noncritical care settings; airway obstruction, desaturation, hypoxia, and apnea have also been reported, most often when used concomitantly with other CNS depressants (eg, opioids). In some cases, where this was not recognized promptly and treated effectively, hypoxic encephalopathy, coma, and death have resulted. Midazolam should be used only in hospital or ambulatory care settings, including physicians' and dentists' offices, that can provide for continuous monitoring of respiratory and cardiac function (eg, pulse oximetry). Immediate availability of resuscitative drugs and age- and size-appropriate equipment for bag/valve/mask ventilation and intubation, and personnel trained in their use and skilled in airway management should be assured. For deeply sedated pediatric patients, a dedicated individual, other than the practitioner performing the procedure, should monitor the patient throughout the procedure.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Risks from concomitant use with opioids:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor patients for respiratory depression and sedation.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Abuse, misuse, and addiction</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The use of benzodiazepines, including midazolam, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing midazolam and throughout treatment, assess each patient's risk for abuse, misuse, and addiction.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Dependence and withdrawal reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The continued use of benzodiazepines may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Although midazolam is indicated only for intermittent use, if used more frequently than recommended, abrupt discontinuation or rapid dosage reduction of midazolam may precipitate acute withdrawal reactions, which can be life-threatening. For patients using midazolam more frequently than recommended, to reduce the risk of withdrawal reactions, use a gradual taper to discontinue midazolam.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Individualization of dosage (injection):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Midazolam must never be used without individualization of dosage. The initial intravenous dose for sedation in adult patients may be as little as 1 mg, but should not exceed 2.5 mg in a healthy adult. Lower doses are necessary for older (&gt;60 years of age) or debilitated patients and in patients receiving concomitant opioids or other CNS depressants. The initial dose and all subsequent doses should always be titrated slowly; administer over at least 2 minutes and allow an additional 2 or more minutes to fully evaluate the sedative effect. The use of the 1 mg/mL formulation or dilution of the 1 mg/mL or 5 mg/mL formulation is recommended to facilitate slower injection. Doses of sedative medications in pediatric patients must be calculated on a mg/kg basis, and initial doses and all subsequent doses should always be titrated slowly. The initial pediatric dose of midazolam for sedation/anxiolysis/amnesia is age, procedure, and route dependent.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Neonates (injection):</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Midazolam should not be administered by rapid injection in the neonatal population. Severe hypotension and seizures have been reported following rapid IV administration, particularly with concomitant use of fentanyl.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F53644605"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Nayzilam</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F196489"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiseizure Agent, Benzodiazepine;</li>
<li>
                        Benzodiazepine</li></ul></div>
<div class="block doa drugH1Div" id="F196447"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5d83f0e9-e3ff-4f25-8e66-a8e628b24efb">Agitation, acute/severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Agitation, acute/severe (monotherapy or adjunctive therapy) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, IM:</b> Initial: 2.5 to 5 mg; repeat doses may be administered every 3 to 5 minutes (IV route) or every 5 to 10 minutes (IM route) until sedation is adequate and appropriate; some patients may require a total dose of ~20 mg; monitor respiratory status; may give alone or in combination with an antipsychotic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29885904','lexi-content-ref-16387219','lexi-content-ref-Moore.1','lexi-content-ref-Roberts.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29885904','lexi-content-ref-16387219','lexi-content-ref-Moore.1','lexi-content-ref-Roberts.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1ff8db39-e6b5-4137-9c50-505e97d85adf">General anesthesia or monitored anesthesia care</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>General anesthesia or monitored anesthesia care: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Individualize dosing based on patient factors and concomitant anesthesia.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Premedication/preinduction: Note:</b> Generally, avoid routine administration as a premedication for general anesthesia due to adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bravenec.1','lexi-content-ref-Joshi.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bravenec.1','lexi-content-ref-Joshi.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> Usual dosing range: 0.5 to 2 mg; administered in 0.5 to 1 mg increments based on clinical effect (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bravenec.1','lexi-content-ref-Rosero.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bravenec.1','lexi-content-ref-Rosero.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Induction (adjunctive agent): Note:</b> Consider reducing dose or avoiding in hemodynamically unstable patients or if already administered with premedication/preinduction. Generally, avoid routine administration for induction of general anesthesia due to adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bravenec.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bravenec.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV: </b>Usual dosing range: 0.5 to 2 mg; administered in 0.5 to 1 mg increments based on clinical effect (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bravenec.1','lexi-content-ref-Jooste.1','lexi-content-ref-Rosero.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bravenec.1','lexi-content-ref-Jooste.1','lexi-content-ref-Rosero.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Use as a sole or co-induction agent is described in the manufacturer's labeling and relevant textbooks (ie, 0.1 to 0.25 mg/kg [premedicated patients] and up to 0.35 mg/kg [unpremedicated patients]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Miller.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Miller.1','lexi-content-ref-manu.1'])">Ref</a></span>); however, this dosing is uncommonly used and may prolong recovery.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d93e0d56-b2c1-4c09-9d4b-fabe64541e4d">Intoxication</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intoxication: Cocaine, </b>
<b>methamphetamine, and other sympathomimetics (alternative agent)</b>
<b> (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note</b>
<b>:</b> If IV access is not available, consider IM administration; however, effect will be delayed (~10 minutes or greater) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Boyer.1','lexi-content-ref-Delgado.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Boyer.1','lexi-content-ref-Delgado.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, IM:</b> 1 to 5 mg every 3 to 10 minutes as needed for agitation, sedation, hyperthermia, hypertension, and tachycardia until desired symptom control is achieved. Large cumulative doses may be required for some patients; monitor for respiratory depression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Boyer.1','lexi-content-ref-Delgado.1','lexi-content-ref-Hoffman.1','lexi-content-ref-28297728']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Boyer.1','lexi-content-ref-Delgado.1','lexi-content-ref-Hoffman.1','lexi-content-ref-28297728'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d6abb6df-ed17-4db8-adf7-fad1b498ff10">Mechanically ventilated patients in the ICU, sedation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mechanically ventilated patients in the ICU, sedation (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note</b>: Used as part of a multimodal strategy. In general, nonbenzodiazepine sedation is preferred due to risk of prolonged sedation and delirium with continuous benzodiazepine use (eg, &gt;48 hours). Intermittent administration is preferred to avoid drug accumulation and prolonged sedation associated with continuous infusions. Titrate to a light level of sedation (eg, Richmond Agitation Sedation Scale 0 to −2) or clinical effect (eg, ventilator dyssynchrony) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30113379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30113379'])">Ref</a></span>). Refer to institutional policies and procedures.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Intermittent:</b> Initial: 0.5 to 5 mg <b>or</b> 0.01 to 0.05 mg/<b>kg</b> over ≥2 minutes; may repeat at 10- to 15-minute intervals as needed until goal level of sedation is achieved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10816184','lexi-content-ref-23269131','lexi-content-ref-Tietze.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10816184','lexi-content-ref-23269131','lexi-content-ref-Tietze.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Continuous infusion:</b> Loading dose: 0.5 to 5 mg every 1 to 5 minutes (if needed), followed by 1 to 8 mg/hour <b>or</b> 0.01 to 0.1 mg/<b>kg</b>/hour continuous infusion; titrate infusion rate to clinical effect. To prevent high basal continuous infusion rates, consider using additional bolus doses instead to achieve goal level of sedation or clinical effect (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10816184','lexi-content-ref-23269131','lexi-content-ref-Tietze.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10816184','lexi-content-ref-23269131','lexi-content-ref-Tietze.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> Consider a daily awakening trial or nurse protocolized sedation; if agitated after discontinuation of continuous infusion, then restart at ~50% of the previous dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10816184','lexi-content-ref-8045143','lexi-content-ref-30113379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10816184','lexi-content-ref-8045143','lexi-content-ref-30113379'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a8ddfdac-ed37-48d5-acd9-1899ba929b46">Palliative and end-of-life sedation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Palliative and end-of-life sedation (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note</b>
<b>: </b>Generally used for management of refractory symptoms (eg, anxiety, agitation, palliative sedation) in addition to an opioid and other medications; use in this setting should be done in close consult with an experienced palliative care provider. Ensure that flumazenil is readily available in the case of inadvertent overdose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25210083','lexi-content-ref-29600413']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25210083','lexi-content-ref-29600413'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, SubQ: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Intermittent:</b> Initial: 1 to 5 mg, then repeat dose every 5 to 15 minutes as needed for symptom management; usual dosage range: 0.25 to 5 mg. <b>Note:</b> Onset of action is delayed with SubQ administration and may influence the frequency of administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cherny.1','lexi-content-ref-25210083','lexi-content-ref-30981104']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cherny.1','lexi-content-ref-25210083','lexi-content-ref-30981104'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Continuous infusion:</b> Initial: 0.25 to 1 mg/hour; titrate as needed for symptom management; usual dosage range: 0.5 to 5 mg/hour; some patients may need up to 20 mg/hour. <b>Note:</b> Generally used after failure of intermittent therapy. SubQ continuous infusion dose is equivalent to IV continuous infusion dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2384705','lexi-content-ref-Cherny.1','lexi-content-ref-25210083','lexi-content-ref-30981104']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2384705','lexi-content-ref-Cherny.1','lexi-content-ref-25210083','lexi-content-ref-30981104'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="edc383a6-1b93-463d-bfc3-4e305f5f3faa">Procedural sedation, outside the operating room</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Procedural sedation, outside the operating room (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Reduce dose when given in conjunction with opioids or other CNS depressants.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>Usual dosage range: 0.5 to 2.5 mg over ≥2 minutes; repeat every 2 to 5 minutes as needed; titrate to clinical effect; maximum total dose: 5 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14528201','lexi-content-ref-Frank.1','lexi-content-ref-Miller.1','lexi-content-ref-Roberts.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14528201','lexi-content-ref-Frank.1','lexi-content-ref-Miller.1','lexi-content-ref-Roberts.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intranasal (using injectable solution) (off-label route):</b> 0.1 mg/kg; administer 15 minutes prior to surgery/procedure; maximum single dose: 10 mg (based on volume) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28366351','lexi-content-ref-12172357']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28366351','lexi-content-ref-12172357'])">Ref</a></span>). <b>Note:</b> Use 5 mg/mL injectable solution to deliver dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28259526','lexi-content-ref-28366351']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28259526','lexi-content-ref-28366351'])">Ref</a></span>). Due to the low pH of the solution, a burning sensation upon administration is likely to occur; consider using an atomizer for delivery or instilling intranasal lidocaine prior to administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24910118','lexi-content-ref-28366351']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24910118','lexi-content-ref-28366351'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="16f9dccd-d560-4631-83e4-036a7dc3f121">Rapid sequence intubation outside the operating room</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rapid sequence intubation outside the operating room (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May cause hypotension; consider alternative agent in patients who are hemodynamically unstable and/or patients with head injury. When used as monotherapy, the onset of action may be up to 5 minutes, which may be too prolonged in some clinical situations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Caro.1','lexi-content-ref-Roberts.2019','lexi-content-ref-24259635']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Caro.1','lexi-content-ref-Roberts.2019','lexi-content-ref-24259635'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 0.2 mg/kg once; use 0.1 mg/kg in hemodynamically unstable patients; usual dosage range: 0.1 to 0.3 mg/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Caro.1','lexi-content-ref-37196592','lexi-content-ref-29413725','lexi-content-ref-Roberts.2019','lexi-content-ref-24259635']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Caro.1','lexi-content-ref-37196592','lexi-content-ref-29413725','lexi-content-ref-Roberts.2019','lexi-content-ref-24259635'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3bdc9ea7-289f-4752-8056-e3eef3f779c9">Seizures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizures:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intermittent (repetitive or cluster): Note:</b> Can be administered by non–health care professionals to patients who are actively seizing or during a seizure cluster. In patients at increased risk of respiratory depression, the first dose should be administered under health care supervision to assess response and tolerability.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Intranasal (Nayzilam nasal spray): </b>5 mg (1 spray) as a single dose in 1 nostril; may repeat same dose in 10 minutes in alternate nostril based on response and tolerability (do not repeat if the patient is having trouble breathing or excessive sedation). Maximum dose: 10 mg (2 sprays) per single episode.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Maximum treatment frequency</i>: Treatment of 1 episode every 3 days and treatment of 5 episodes in 1 month.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Status epilepticus (convulsive and nonconvulsive):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> IM midazolam is the preferred benzodiazepine in patients <i>without</i> IV access. Intranasal and buccal administration are effective alternatives in patients <i>without</i> IV access (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26900382','lexi-content-ref-28259526','lexi-content-ref-22528274','lexi-content-ref-10985999']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26900382','lexi-content-ref-28259526','lexi-content-ref-22528274','lexi-content-ref-10985999'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM:</b> 10 mg once or 0.2 mg/kg once (maximum dose: 10 mg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26900382','lexi-content-ref-22528274','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26900382','lexi-content-ref-22528274','lexi-content-ref-manu.1'])">Ref</a></span>). <b>Note:</b> Only the injectable product Seizalam is FDA approved for status epilepticus; however, any parenteral product approved for IM administration may be used off label for this indication.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Intranasal (may use injectable solution) (off-label route): </b>Initial: 5 to 10 mg. May repeat dose if needed; maximum total dose: 15 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Drislane.1','lexi-content-ref-31682078','lexi-content-ref-22528274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Drislane.1','lexi-content-ref-31682078','lexi-content-ref-22528274'])">Ref</a></span>). <b>Note:</b> May use 5 mg/mL parenteral concentrated solution to deliver dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28435493']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28435493'])">Ref</a></span>). Due to the low pH of the solution, a burning sensation upon administration is likely to occur; consider using an atomizer for delivery or instilling intranasal lidocaine prior to administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24910118','lexi-content-ref-28366351']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24910118','lexi-content-ref-28366351'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Buccal (may use injectable solution) (off-label route):</b> Initial: 10 mg. May repeat dose if needed; maximum total dose: 30 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21208198','lexi-content-ref-22528274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21208198','lexi-content-ref-22528274'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Status epilepticus, refractory (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note</b>
<b>:</b> Mechanical ventilation and hemodynamic support generally required; titrate dose to cessation of electrographic seizures or burst suppression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27544138','lexi-content-ref-22528274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27544138','lexi-content-ref-22528274'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Loading dose:</b> 0.2 mg/kg administered slowly, followed by a continuous infusion; repeat loading dose every 3 to 5 minutes (maximum total dose: 2 mg/kg) as needed for electrographic/burst suppression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Drislane.1','lexi-content-ref-27544138','lexi-content-ref-22528274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Drislane.1','lexi-content-ref-27544138','lexi-content-ref-22528274'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Continuous infusion:</b> After initial loading dose, begin continuous infusion at 0.05 to 2 mg/kg/<b>hour</b> and titrate to cessation of electrographic seizures/burst suppression. For breakthrough status epilepticus, administer bolus of 0.1 to 0.2 mg/kg every 3 to 5 minutes in addition to increasing infusion rate by 0.05 to 0.1 mg/kg/<b>hour</b> every 3 to 4 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27544138','lexi-content-ref-22528274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27544138','lexi-content-ref-22528274'])">Ref</a></span>). Some experts use doses up to 3 mg/kg/<b>hour</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Drislane.1','lexi-content-ref-24363133','lexi-content-ref-27544138']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Drislane.1','lexi-content-ref-24363133','lexi-content-ref-27544138'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> Generally, a period of at least 24 hours of electrographic suppression is suggested prior to down titrating the continuous infusion; withdraw gradually by decreasing the dose 50% every 3 hours to prevent recurrent status epilepticus or taper off over 4 to 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Drislane.1','lexi-content-ref-24363133','lexi-content-ref-27544138']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Drislane.1','lexi-content-ref-24363133','lexi-content-ref-27544138'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990675"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Use with caution in kidney dysfunction and/or those receiving renal replacement therapies. The half-life of midazolam and active metabolites are prolonged in acutely ill patients with acute kidney injury receiving continuous infusions and may accumulate, contributing to prolonged sedation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7603229','lexi-content-ref-17316150','lexi-content-ref-30981104']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7603229','lexi-content-ref-17316150','lexi-content-ref-30981104'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Buccal, intranasal, parenteral:</b> No initial dosage adjustments necessary for any degree of kidney impairment; however, use with caution and monitor closely for excessive sedation in patients with severe impairment (eg, CrCl &lt;30 mL/minute); consider longer dosing intervals for intermittent dosing and slower titration of continuous infusions. In some situations (eg, sedation in mechanically ventilated patients) additional boluses may be considered to prevent higher basal continuous infusion rates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly): Buccal, intranasal, parenteral:</b> Unlikely to be significantly dialyzable (highly protein bound) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">No initial dosage adjustments necessary; however, use with caution and monitor closely for excessive sedation; consider longer dosing intervals for intermittent dosing and slower titration of continuous infusions. In some situations (eg, sedation in mechanically ventilated patients), additional boluses may be considered to prevent higher basal continuous infusion rates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis: </b>Unlikely to be significantly dialyzable (highly protein bound) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Buccal, intranasal, parenteral:</b> No initial dosage adjustments necessary; however, use with caution and monitor closely for excessive sedation; consider longer dosing intervals for intermittent dosing and slower titration of continuous infusions. In some situations (eg, sedation in mechanically ventilated patients) additional boluses may be considered to prevent higher basal continuous infusion rates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b>
<b>Buccal, intranasal, </b>
<b>parenteral:</b> Midazolam and 1-hydroxy-midazolam (active metabolite) are not effectively removed by CRRT, although 1-alpha hydroxymidazolam glucuronide (also hypothesized to be active) is significantly removed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11549100','lexi-content-ref-15685515']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11549100','lexi-content-ref-15685515'])">Ref</a></span>). No initial dosage adjustments necessary; however, use with caution and monitor closely for excessive sedation; consider longer dosing intervals for intermittent dosing and slower titration of continuous infusions. In some situations (eg, sedation in mechanically ventilated patients) additional boluses may be considered to prevent higher basal continuous infusion rates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b>
<b>Buccal, intranasal, </b>
<b>parenteral:</b> Midazolam and 1-hydroxymidazolam are not expected to be effectively removed by PIRRT, although 1-alpha hydroxymidazolam glucuronide (also hypothesized to be active) may be significantly removed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). No initial dosage adjustments necessary; however, use with caution and monitor closely for excessive sedation; consider longer dosing intervals for intermittent dosing and slower titration of continuous infusions. In some situations (eg, sedation in mechanically ventilated patients), additional boluses may be considered to prevent higher basal continuous infusion rates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987939"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">IV:</p>
<p style="text-indent:-2em;margin-left:4em;">Single dose (eg, induction): No dosage adjustment recommended; patients with hepatic impairment may be more sensitive compared to patients without hepatic impairment; anticipate longer duration of action (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2936661','lexi-content-ref-3395535']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2936661','lexi-content-ref-3395535'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Multiple dosing or continuous infusion: Expect longer duration of action and accumulation; based on patient response, dosage reduction likely to be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3395535']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3395535'])">Ref</a></span>).</p></div>
<div class="block doo drugH1Div" id="F56687431"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">The recommendations for dosing in patients with obesity are based upon the best available evidence and clinical expertise. Senior Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Class 1, 2, and 3 obesity (BMI ≥30 kg/m<sup>2</sup>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intermittent:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV, IM, SUBQ, intranasal</b> (using injectable solution): Use of non–weight-based dosing is preferred; titrate to clinical effect if needed (expert opinion). If weight-based doses are utilized, use <b>adjusted body weight</b> for initial weight-based dosing calculations, then titrate to clinical effect if needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOO']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOO'])">Ref</a></span>). If rapid sedation or clinical effect is needed, use <b>actual body weight</b> for initial weight-based dose calculations, then titrate to clinical effect (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOO']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOO'])">Ref</a></span>). Clinicians should <b>not</b> change dosing weight from one weight metric to another during therapy (ie, actual body weight to/from adjusted body weight) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOO']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOO'])">Ref</a></span>). Refer to adult dosing for indication-specific doses.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Continuous infusion:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> Use of non–weight-based dosing is preferred; titrate to clinical effect (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOO']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOO'])">Ref</a></span>). If weight-based doses are utilized, use <b>adjusted body weight</b> for initial weight-based dosing calculations, then titrate to clinical effect (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOO']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOO'])">Ref</a></span>). Clinicians should <b>not</b> change dosing weight from one weight metric to another during therapy (ie, actual body weight to/from adjusted body weight) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOO']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOO'])">Ref</a></span>). Refer to adult dosing for indication-specific dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rationale for recommendations:</b></p>
<p style="text-indent:-2em;margin-left:4em;">There are limited data on the effects of obesity on midazolam dosing or pharmacokinetics. Midazolam pharmacokinetic studies in subjects with obesity have described an increased V<sub>d</sub> with no difference in clearance compared to subjects without obesity. The reported half-life is therefore longer in patients with obesity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25141974','lexi-content-ref-6742481']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25141974','lexi-content-ref-6742481'])">Ref</a></span>). Due to the increased V<sub>d</sub>, these pharmacokinetic data suggest larger doses may be required. However, larger doses may increase the adverse drug effects particularly in select populations (eg, elderly or nonintubated patients). Furthermore, since obesity does not influence clearance, there may be a potential for accumulation with repeat dosing or continuous infusions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32513237']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32513237'])">Ref</a></span>). In general, smaller doses that can be rapidly titrated to effect are preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32513237']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32513237'])">Ref</a></span>).</p></div>
<div class="block doe drugH1Div" id="F196448"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Avoid use; may be appropriate for seizure disorders and periprocedural anesthesia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intranasal (nasal spray):</b> Refer to adult dosing; use with caution due to potential prolonged drug exposure.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Parenteral:</b> Refer to adult dosing; midazolam needs to be individualized based on the patient's age, underlying diseases, and concurrent medications. Consider reducing dose by 20% to 50% in elderly, chronically ill, or debilitated patients and those receiving opioids or other CNS depressants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Miller.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Miller.1'])">Ref</a></span>). Titration of doses should also be slower (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27798767']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27798767'])">Ref</a></span>).</p></div>
<div class="block dop drugH1Div" id="F196467"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12611" href="/d/html/12611.html" rel="external">see "Midazolam: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Dosage must be individualized and based on patient's age, underlying diseases, concurrent medications, and desired effect; calculate dose based on ideal body weight for patients with obesity; allow 3 to 5 minutes between IV doses to decrease the chance of oversedation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> The nasal spray formulation delivers a fixed dose of 5 mg and is not appropriate for all pediatric patients; for smaller intranasal doses, parenteral solution for injection can be used; ensure appropriate product selection and administration technique.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a7583f66-7df5-4b23-ba96-a979b90ba6ee">Sedation, anxiolysis, and amnesia prior to procedure or before induction of anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sedation, anxiolysis, and amnesia prior to procedure or before induction of anesthesia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">IM: Infants, Children, and Adolescents: IM: Usual dose: 0.1 to 0.15 mg/kg 30 to 60 minutes before surgery or procedure; range: 0.05 to 0.15 mg/kg; doses up to 0.5 mg/kg have been used in more anxious patients; maximum total dose: 10 mg.</p>
<p style="text-indent:-2em;margin-left:4em;">IV:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants &lt;6 months: IV: Limited data available in nonintubated infants; infants &lt;6 months are at higher risk for airway obstruction and hypoventilation; titrate dose with small increments to desired clinical effect; monitor carefully.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥6 months to Children &lt;6 years: IV: Initial: 0.05 to 0.1 mg/kg; titrate dose carefully to desired clinical effect; total dose of 0.6 mg/kg may be required; usual maximum total dose: 6 mg.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥6 years: IV: Initial: 0.025 to 0.05 mg/kg; titrate dose carefully to desired clinical effect; total doses of 0.4 mg/kg may be required; usual maximum total dose: 10 mg.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: IV: Initial: 1 to 2.5 mg over ≥2 minutes; titrate dose carefully to desired clinical effect; usual maximum total dose: 10 mg. <b>Note: </b>Based on experience in adults, smaller initial doses (eg, 0.5 mg) may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14528201']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14528201'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Intranasal: Limited data available: <b>Note:</b> Administer using parenteral solution for injection product via intranasal route; use of mucosal atomizer device (MAD) is recommended.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: Intranasal: Usual dose: 0.2 mg/kg as a single dose, may repeat in 15 minutes; reported range: 0.2 to 0.8 mg/kg; maximum dose: 10 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11310461','lexi-content-ref-29364490','lexi-content-ref-7567258','lexi-content-ref-18496113','lexi-content-ref-33089024','lexi-content-ref-17127776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11310461','lexi-content-ref-29364490','lexi-content-ref-7567258','lexi-content-ref-18496113','lexi-content-ref-33089024','lexi-content-ref-17127776'])">Ref</a></span>). <b>Note:</b> Some investigators suggest premedication with intranasal lidocaine to decrease irritation and subsequent agitation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21030365','lexi-content-ref-8414846']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21030365','lexi-content-ref-8414846'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Infants ≥6 months, Children, and Adolescents &lt;16 years: Oral: Single dose: 0.25 to 0.5 mg/kg once, depending on patient status and desired effect, usual: 0.5 mg/kg; maximum dose: 20 mg; <b>Note:</b> Younger patients (6 months to &lt;6 years) and those less cooperative may require higher doses (up to 1 mg/kg) compared to patients 6 years to &lt;16 years, who may only require 0.25 mg/kg; use lower initial doses (0.25 mg/kg) in all patients with cardiac or respiratory compromise, concomitant CNS depressant, or high-risk surgical patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Rectal: Limited data available: Infants &gt;6 months and Children: Rectal: Usual: 0.25 to 0.5 mg/kg once (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16517277','lexi-content-ref-29805070']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16517277','lexi-content-ref-29805070'])">Ref</a></span>); doses up to 1 mg/kg have been used in infants and young children (7 months to 5 years of age) but may be associated with a higher incidence of postprocedural agitation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14578832','lexi-content-ref-11046209']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14578832','lexi-content-ref-11046209'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="eebde992-d4c4-4a2d-8298-3c4812cd280a">Sedation, mechanically ventilated patient</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sedation, mechanically ventilated patient: </b>Infants, Children, and Adolescents: IV: Loading dose: 0.05 to 0.2 mg/kg given slow IV over ≥2 to 3 minutes, then follow with initial continuous IV infusion: 0.05 to 0.12 mg/kg/<b>hour</b> (0.8 to 2 <b>mcg</b>/kg/minute); titrate to the desired effect; maximum initial dose: 10 mg/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25602358','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25602358','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Sedation tapering (after prolonged therapy):</i> After prolonged therapy, consider a slow taper of therapy or conversion to a long-acting benzodiazepine to prevent signs and symptoms of withdrawal. Reported conversion strategies are based on potency, half-life, and oral bioavailability of diazepam and lorazepam but are variable and based on limited clinical evidence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10890677','lexi-content-ref-29570859','lexi-content-ref-30080777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10890677','lexi-content-ref-29570859','lexi-content-ref-30080777'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">If duration of therapy &lt;3 to 5 days: Decrease dose by 10% to 15% every 6 to 8 hours (Tobias 2000); monitor closely for signs and symptoms of withdrawal with each reduction in dose.</p>
<p style="text-indent:-2em;margin-left:6em;">If duration of therapy &gt;5 days, the following regimens have been reported:</p>
<p style="text-indent:-2em;margin-left:8em;">Conversion to oral diazepam: After first dose of oral diazepam, decrease midazolam infusion by 50%; after the second dose of oral diazepam, discontinue the midazolam infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30080777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30080777'])">Ref</a></span>); monitor closely for signs and symptoms of withdrawal with each reduction in dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Conversion to oral lorazepam: After second dose of oral lorazepam, decrease midazolam infusion by 50%; after third dose of oral lorazepam, decrease the midazolam infusion by an additional 50%; after fourth dose of oral lorazepam, discontinue the midazolam infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10890677','lexi-content-ref-29570859']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10890677','lexi-content-ref-29570859'])">Ref</a></span>); monitor closely for signs and symptoms of withdrawal with each reduction in dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="90f0e75b-d4ea-42d3-8ff0-2ae4051421da">Seizures, acute treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizures, acute treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Buccal: Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32387007','lexi-content-ref-20554464','lexi-content-ref-12767460','lexi-content-ref-16023510','lexi-content-ref-18166545','lexi-content-ref-19114297']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32387007','lexi-content-ref-20554464','lexi-content-ref-12767460','lexi-content-ref-16023510','lexi-content-ref-18166545','lexi-content-ref-19114297'])">Ref</a></span>): <b>Note:</b> Reserve for patients without IV access; if seizure does not cease within 5 minutes, some studies describe repeating dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12767460']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12767460'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Weight-directed dosing: Infants ≥3 months, Children, and Adolescents: Buccal: 0.2 to 0.5 mg/kg once; maximum dose: 10 mg/dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Age-directed dosing:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants ≥3 months: Buccal: 2.5 mg.</p>
<p style="text-indent:-2em;margin-left:8em;">Children 1 to 4 years: Buccal: 5 mg.</p>
<p style="text-indent:-2em;margin-left:8em;">Children 5 to 9 years: Buccal: 7.5 mg.</p>
<p style="text-indent:-2em;margin-left:8em;">Children and Adolescents ≥10 years: Buccal: 10 mg.</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Limited data available:</p>
<p style="text-indent:-2em;margin-left:6em;">Weight-directed dosing: Infants, Children, and Adolescents: IM: 0.2 mg/kg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Fixed dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">13 to 40 kg: IM: 5 mg.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;40 kg: IM: 10 mg.</p>
<p style="text-indent:-2em;margin-left:4em;">Intranasal:</p>
<p style="text-indent:-2em;margin-left:6em;">Nasal spray (Nayzilam): Children ≥12 years and Adolescents: Intranasal: 5 mg administered as 1 spray into 1 nostril; may repeat dose in 10 minutes in alternate nostril based on response and tolerability; do not repeat dose if patient has difficulty breathing or excessive sedation; maximum dose: 10 mg/dose per episode (2 sprays); do not exceed maximum treatment frequency of 1 episode every 3 days and 5 episodes per month.</p>
<p style="text-indent:-2em;margin-left:6em;">Parenteral solution for injection product: Limited data available: Use of mucosal atomizer device (MAD) is recommended:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants, Children, and Adolescents: Intranasal (using parenteral solution): 0.2 mg/kg/dose, divide dose between nares; maximum dose: 10 mg/dose; may repeat once to a total maximum of 0.4 mg/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16647994','lexi-content-ref-11198507','lexi-content-ref-11952072','lexi-content-ref-20679166','lexi-content-ref-17413428']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16647994','lexi-content-ref-11198507','lexi-content-ref-11952072','lexi-content-ref-20679166','lexi-content-ref-17413428'])">Ref</a></span>). <b>Note:</b> A higher dose of 0.3 mg/kg has been described in patients ≥6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11042416']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11042416'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="98f720da-4e7e-4163-a85a-e8df3fee1f21">Status epilepticus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Status epilepticus: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Standard treatment</i>: Infants, Children, and Adolescents: Limited data available:</p>
<p style="text-indent:-2em;margin-left:6em;">IM:</p>
<p style="text-indent:-2em;margin-left:8em;">Weight-based dosing: IM: 0.2 mg/kg once; maximum dose: 10 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22528274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22528274'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Fixed dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26900382','lexi-content-ref-22528274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26900382','lexi-content-ref-22528274'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:10em;">13 to 40 kg: IM: 5 mg once.</p>
<p style="text-indent:-2em;margin-left:10em;">&gt;40 kg: IM: 10 mg once.</p>
<p style="text-indent:-2em;margin-left:6em;">Intranasal: 0.2 mg/kg once; maximum dose: 10 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26900382','lexi-content-ref-22528274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26900382','lexi-content-ref-22528274'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Buccal: 0.5 mg/kg once; maximum dose: 10 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26900382','lexi-content-ref-16023510','lexi-content-ref-22528274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26900382','lexi-content-ref-16023510','lexi-content-ref-22528274'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Refractory to standard treatment</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22528274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22528274'])">Ref</a></span>): <b>Note:</b> Mechanical ventilation and cardiovascular monitoring required; titrate dose to cessation of electrographic seizures or burst suppression. Infants, Children, and Adolescents: Limited data available:</p>
<p style="text-indent:-2em;margin-left:6em;">Loading dose: IV: 0.2 mg/kg followed by a continuous infusion.</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous IV infusion: 0.05 to 2 mg/kg/<b>hour</b> (0.83 to 33.3 <b>mcg</b>/kg/minute) titrated to cessation of electrographic seizures or burst suppression. If patient experiences breakthrough status epilepticus while on the continuous infusion, administer a bolus of 0.1 to 0.2 mg/kg and increase infusion rate by 0.05 to 0.1 mg/kg/<b>hour</b> (0.83 to 1.66 <b>mcg</b>/kg/minute) every 3 to 4 hours.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51130731"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution; half-life of midazolam and metabolites may be prolonged. Adult patients with renal failure receiving a continuous infusion cannot adequately eliminate the active hydroxylated metabolites (eg, 1-hydroxymidazolam) contributing to prolonged sedation sometimes for days after discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17316150']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17316150'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Supplemental dose is not necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Peritoneal dialysis: Significant drug removal is unlikely based on physiochemical characteristics</p></div>
<div class="block dohp drugH1Div" id="F51130732"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution. Based on experience in adult patients, the following have been suggested and may be considered in pediatric patients:</p>
<p style="text-indent:-2em;margin-left:2em;">Single dose (eg, induction): No dosage adjustment recommended; patients with hepatic impairment may be more sensitive compared to patients without hepatic impairment; anticipate longer duration of action (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2936661','lexi-content-ref-3395535']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2936661','lexi-content-ref-3395535'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Multiple dosing or continuous infusion: Expect longer duration of action and accumulation; based on patient response, dosage reduction likely to be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3395535']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3395535'])">Ref</a></span>).</p></div>
<div class="block adr drugH1Div" id="F196406"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. As reported in children, adolescents, and adults unless otherwise noted. Intranasal only adverse reactions include adolescents and adults. Oral only adverse reactions include children and adolescents.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Vomiting (≤11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Apnea (adults: 15%; children: 3%), bradypnea (adults: ≤23%), decreased tidal volume (adults: ≤23%), nasal discomfort (intranasal: 5% to 16%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrioventricular nodal arrhythmia (≤1%), bigeminy (≤2%), bradycardia (≤2%), hypotension (≤3%), syncope (≤1%), tachycardia (≤1%), ventricular premature contractions (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (≤1%), skin rash (≤2%), urticaria (≤1%), urticaria at injection site (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Acidic taste (≤1%), dysgeusia (intranasal: 4%), hiccups (1% to 4%), nausea (2% to 5%), retching (≤1%), sialorrhea (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hematoma (≤1%), oxygen desaturation (≤5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (≤1%), hypersensitivity reaction (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Burning sensation at injection site (≤1%), erythema at injection site (adults: ≤3%), induration at injection site (adults: ≤2%), injection site reaction (coldness: ≤1%), pain at injection site (adults: 4% to 5%), swelling at injection site (≤1%), tenderness at injection site (adults: 6%), warm sensation at injection site (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams (emergence: 1%), agitation (≤4%, including emergence agitation), anxiety (≤1%), ataxia (≤1%), athetosis (≤1%), behavioral changes (argumentativeness: ≤1%), chills (≤1%), confusion (≤1%), delirium (emergence: ≤1%), dizziness (≤1%), drowsiness (injection [adults]: 1%; intranasal: 9% to 10%), dysarthria (intranasal: 2%), dysphoria (≤1%), euphoria (≤1%), hallucination (≤1%), headache (adults and adolescents: 1% to 7%), impaired consciousness (adults: 3%), insomnia (≤1%), intoxicated feeling (≤1%), lethargy (≤1%), loss of balance (≤1%), mental status changes (adults: 3%), nervousness (≤1%), nightmares (≤1%), paresthesia (≤1%), prolonged emergence from anesthesia (≤1%), psychiatric signs and symptoms (oral: ≤3%), restlessness (≤1%), retrograde amnesia (≤1%), sedated state (prolonged: oral: 2%), seizure-like activity (≤1%), severe sedation (adults: 2%), sleep disturbance (≤1%), slurred speech (≤1%), voice disorder (≤1%), yawning (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (≤1%), laryngospasm (≤4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Accommodation disturbance (≤1%), blurred vision (≤1%), diplopia (≤1%), increased lacrimation (intranasal: 1% to 2%), miosis (≤1%), nystagmus disorder (≤1%), visual disturbance (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Blockage of external ear (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute renal failure (adults: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Airway obstruction (≤5%), bronchospasm (≤1%), cough (adults: 1%), dyspnea (≤1%), hyperventilation (≤1%), hypoxia (oral: 3% to 4%), respiratory congestion (upper; oral: 2%), respiratory depression (≤2%), rhinorrhea (intranasal and oral: ≤5%), rhonchi (children: ≤2%), shallow respiration (≤1%), tachypnea (≤1%), throat irritation (intranasal: 2% to 7%), wheezing (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (adults: 4%), paradoxical reaction (children: 2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site phlebitis</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle rigidity</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Sneezing</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aggressive behavior, cognitive dysfunction, drug dependence (physical and psychological dependence with prolonged use), hyperactive behavior, involuntary body movements, suicidal ideation, suicidal tendencies, tonic-clonic movements</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Tremor</p></div>
<div class="block coi drugH1Div" id="F196422"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Injection, oral: Hypersensitivity to midazolam or any component of the formulation; intrathecal or epidural injection of parenteral forms containing preservatives (ie, benzyl alcohol); use in premature infants for parenteral forms containing benzyl alcohol; acute narrow-angle glaucoma.</p>
<p style="text-indent:-2em;margin-left:4em;">Concurrent use of oral midazolam with protease inhibitors (atazanavir, atazanavir-cobicistat, darunavir, indinavir, lopinavir-ritonavir, nelfinavir, ritonavir, saquinavir, tipranavir); concurrent use of oral or injectable midazolam with fosamprenavir.</p>
<p style="text-indent:-2em;margin-left:4em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">Intranasal: Hypersensitivity to midazolam or any component of the formulation; acute narrow-angle glaucoma.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Injection: Acute pulmonary insufficiency; severe chronic obstructive pulmonary disease; IV sedation in elderly or debilitated patients outside ICU setting and in patients not sufficiently alert to respond appropriately to verbal requests.</p></div>
<div class="block war drugH1Div" id="F196403"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anterograde amnesia: Benzodiazepines have been associated with anterograde amnesia (Nelson 1999).</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiorespiratory effects: Serious cardiorespiratory adverse events have occurred with midazolam administration, including cardiac arrest, permanent neurologic injury, and death. Risk of adverse events is increased in patients with abnormal airway anatomy, cyanotic congenital heart disease, sepsis, or severe pulmonary disease. In patients with a risk of respiratory depression, consider administering the first dose of intranasal midazolam under health care supervision; this may be performed in the absence of a seizure episode.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving). A minimum of one day should elapse after midazolam administration before attempting these tasks. Elapsed time to resume these tasks must be individualized, as pharmacologic effects are dependent on dose, route, duration of procedure, and presence of other medications.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypotension: May cause hypotension, particularly in pediatric patients or patients with hemodynamic instability. Hypotension may occur more frequently in patients who have received opioid analgesics.</p>
<p style="text-indent:-2em;margin-left:4em;">• Paradoxical reactions: Paradoxical reactions, including hyperactive or aggressive behavior, have been reported with benzodiazepines; risk may be increased in adolescent/pediatric patients, older adults, or patients with a history of alcohol use disorder or psychiatric/personality disorders (Mancuso 2004). Midazolam may cause involuntary movements (eg, tonic/clonic movements, tremor) and combativeness when used for sedation; may cause agitation when used for sedation or status epilepticus. Reactions may be due to improper dosing or administration; cerebral hypoxia should also be considered as a cause.</p>
<p style="text-indent:-2em;margin-left:4em;">• Suicidal ideation: Intranasal: Pooled analysis of trials involving various antiseizure medications (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as one week after initiation and continued through duration of trials (most trials ≤24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify health care provider immediately if symptoms occur.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acute illness: Use IV midazolam with caution in patients with uncompensated acute illnesses, such as severe fluid or electrolyte disturbances.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with heart failure. Adverse hemodynamic events have been reported in pediatric patients with cardiovascular instability; avoid rapid IV administration in these patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Glaucoma: Use with caution in patients with glaucoma; may increase intraocular pressure. May consider use in patients with open-angle glaucoma only if receiving appropriate therapy; consider evaluating ophthalmologic status after midazolam use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; half-life of midazolam and metabolites may be prolonged.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory disease: Reduce dose or avoid use in patients with respiratory disease, including chronic obstructive pulmonary disease or sleep apnea. Benzodiazepines may cause significant respiratory depression.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Debilitated patients: Use with caution in debilitated patients; decreased dosages recommended. These patients take longer to recover completely after midazolam administration for the induction of anesthesia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Fall risk: Use with extreme caution in patients who are at risk of falls; benzodiazepines have been associated with falls and traumatic injury (Nelson 1999).</p>
<p style="text-indent:-2em;margin-left:4em;">• Neonates: Injection: Neonates are vulnerable to profound and/or prolonged respiratory effects of midazolam.</p>
<p style="text-indent:-2em;margin-left:4em;">• Obesity: Use benzodiazepines with caution in patients with obesity; may have prolonged action when discontinued.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adults: Use with caution in older adults; decreased dosages and slower titration is recommended due to an increased volume of distribution seen with lipophilic drugs in older adults, resulting in slower distribution and lower clearance. The risk of hypoventilation, airway obstruction, and apnea is higher in older patients. Older adults can also take longer to recover completely after midazolam administration for the induction of anesthesia (Strøm 2016). Use of oral midazolam is not recommended in older adults. Older adults may be at an increased risk of death with use; risk has been found highest within the first 4 months of use in older patients with dementia (Jennum 2015; Saarelainen 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Pediatric patients with cardiac or respiratory compromise may be sensitive to the respiratory depressant effect of midazolam. Pediatric patients undergoing procedures involving the upper airway (eg, upper endoscopy, dental care) are vulnerable to episodes of desaturation and hypoventilation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric neurotoxicity: In pediatric and neonatal patients &lt;3 years of age and patients in third trimester of pregnancy (ie, times of rapid brain growth and synaptogenesis), the repeated or lengthy exposure to sedatives or anesthetics during surgery/procedures may have detrimental effects on child or fetal brain development and may contribute to various cognitive and behavioral problems. Epidemiological studies in humans have reported various cognitive and behavioral problems, including neurodevelopmental delay (and related diagnoses), learning disabilities, and attention-deficit hyperactivity disorder. Human clinical data suggest that single, relatively short exposures are not likely to have similar negative effects. No specific anesthetic/sedative has been found to be safer. For elective procedures, risk versus benefits should be evaluated and discussed with parents/caregivers/patients; critical surgeries should not be delayed (US FDA Safety Communication 2017 Update).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity ("gasping syndrome") in neonates; the "gasping syndrome" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggest that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Abuse, misuse, and substance use disorder: Counsel patients at increased risk on proper use and monitoring for signs and symptoms of abuse, misuse, and substance use disorder. Institute early treatment or refer patients in whom substance use disorder is suspected. Limit dosages and durations to the minimum required; counsel on proper disposal of unused drug.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Does not have analgesic, antidepressant, or antipsychotic properties. Does not protect against increases in intracranial pressure, heart rate, and/or blood pressure during intubation. Do not use in shock, coma, or acute alcohol intoxication with depression of vital signs. Avoid intra-arterial administration or extravasation of parenteral formulations. Use during upper airway procedures (ie, endoscopy, dental care) may increase risk of hypoventilation. Prolonged responses have been noted following extended administration by continuous infusion (possibly due to metabolite accumulation) or in the presence of drugs which inhibit midazolam metabolism. Oral midazolam is intended for use in monitored settings only and not for chronic or home use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dependence and withdrawal reactions: Some patients may develop a protracted withdrawal syndrome lasting &gt;12 months; may be difficult to differentiate withdrawal symptoms from reemergence or continuation of symptoms for which benzodiazepines were prescribed. Flumazenil may cause withdrawal in patients receiving long-term benzodiazepine therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tolerance: Midazolam is a short half-life benzodiazepine and may be of benefit in patients where a rapidly and short-acting agent is desired (eg, for acute agitation). Duration of action after a single dose is determined by redistribution rather than metabolism. Tolerance develops to the sedative and antiseizure effects. It does not develop to the anxiolytic effects (Vinkers 2012).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878550"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">In pediatric and neonatal patients &lt;3 years of age and patients in third trimester of pregnancy (ie, times of rapid brain growth and synaptogenesis), the repeated or lengthy exposure to sedatives or anesthetics during surgery/procedures may have detrimental effects on the child's or fetus' brain development and may contribute to various cognitive and behavioral problems; the FDA is requiring warnings be included in the manufacturer's labeling for all general anesthetic/sedative drugs. Multiple animal species studies have shown adverse effects on brain maturation; in juvenile animals, drugs that potentiate GABA activity and/or block NMDA receptors for &gt;3 hours demonstrated widespread neuronal and oligodendrocyte cell loss along with alteration in synaptic morphology and neurogenesis. Epidemiological studies in humans have reported various cognitive and behavioral problems including neurodevelopmental delay (and related diagnoses), learning disabilities, and attention-deficit/hyperactivity disorder. Human clinical data suggest that single, relatively short exposures are not likely to have similar negative effects. Further studies are needed to fully characterize findings and ensure that these findings are not related to underlying conditions or the procedure itself. No specific anesthetic/sedative has been found to be safer. For elective procedures, risk vs benefits should be evaluated and discussed with parents/caregivers/patients; critical surgeries should not be delayed (FDA 2017; McCann 2019; Sun 2016).</p>
<p style="text-indent:0em;margin-top:2em;">In neonates, particularly premature neonates, several cases of myoclonus (rhythmic myoclonic jerking) have been reported (~8% incidence).</p></div>
<div class="block foc drugH1Div" id="F196415"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg/2 mL (2 mL); 5 mg/5 mL (5 mL); 10 mg/10 mL (10 mL); 5 mg/mL (1 mL); 10 mg/2 mL (2 mL); 25 mg/5 mL (5 mL); 50 mg/10 mL (10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg/2 mL (2 mL); 5 mg/5 mL (5 mL); 5 mg/mL (1 mL); 10 mg/2 mL (2 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/100 mL in NaCl 0.8% (100 mL); 50 mg/50 mL in NaCl 0.8% (50 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/100 mL in NaCl 0.8% (100 mL); 100 mg/100 mL in NaCl 0.9% (100 mL); 50 mg/50 mL in NaCl 0.9% (50 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Nasal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nayzilam: 5 mg/0.1 mL (1 ea) [contains propylene glycol]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Syrup, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg/mL (2.5 mL [DSC], 5 mL, 118 mL)</p></div>
<div class="block geq drugH1Div" id="F196399"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323409"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Midazolam HCl (PF) Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg/2 mL (per mL): $0.64 - $1.88</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/5 mL (per mL): $0.26 - $0.27</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/mL (per mL): $1.38 - $2.98</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/2 mL (per mL): $0.74 - $0.82</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Midazolam HCl Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg/2 mL (per mL): $0.19 - $0.68</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/5 mL (per mL): $0.13 - $0.68</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/mL (per mL): $1.44 - $3.43</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/10 mL (per mL): $0.26 - $0.68</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/2 mL (per mL): $0.75 - $3.38</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg/5 mL (per mL): $1.17 - $1.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/10 mL (per mL): $0.23 - $3.64</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Midazolam HCl-Sodium Chloride Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50MG/50ML 0.8% (per mL): $0.29</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100MG/100ML 0.8% (per mL): $0.26</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Midazolam-Sodium Chloride (PF) Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100MG/100ML 0.8% (per mL): $0.30</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Midazolam-Sodium Chloride Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/50 mL 0.9% (per mL): $0.53</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/100 mL 0.9% (per mL): $0.36</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Nayzilam Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5MG/0.1ML (per each): $390.40</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Syrup</b> (Midazolam HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg/mL (per mL): $1.48</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867558"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg/mL (2 mL, 5 mL, 10 mL, 100 mL); 5 mg/mL (1 mL, 2 mL, 10 mL, 50 mL); 50 mg/10 mL (10 mL)</p></div>
<div class="block csi drugH1Div" id="F196491"><span class="drugH1">Controlled Substance</span>
<p style="text-indent:0em;display:inline">C-IV</p></div>
<div class="block adm drugH1Div" id="F196419"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Buccal (off-label route):</b> A buccal formulation is not currently available in the US. Some trials used an injectable solution administered buccally (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16023510']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16023510'])">Ref</a></span>). International studies used a 10 mg/mL commercially available buccal formulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20554464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20554464'])">Ref</a></span>). Administer to the buccal mucosa between the gums and the cheek using an oral syringe; gently massage cheek; dose may be divided to both sides of the mouth (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20554464','lexi-content-ref-16023510']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20554464','lexi-content-ref-16023510'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intranasal:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Nasal spray: Do not test or prime before use. Administer 1 spray into 1 nostril; if a second dose is needed, administer in alternate nostril. A second dose should not be administered if the patient is having trouble breathing or excessive sedation.</p>
<p style="text-indent:-2em;margin-left:4em;">Solution, injection (off-label route):<b> Note:</b> Due to the low pH of the solution, burning upon administration is likely to occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24910118']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24910118'])">Ref</a></span>). Use of an atomizer, such as the MAD 300 Mucosal Atomizer which attaches to a tuberculin syringe, can reduce irritation. If possible, based upon dose to be administered, use higher concentration injectable solution to minimize volume administered intranasal. Smaller volume will reduce irritation and swallowing of administered dose. The maximum recommended dose volume (of the 5 mg/mL concentration) per nare is 1 mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28259526']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28259526'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Using the 5 mg/mL injectable solution, draw up desired dose with a 1 to 3 mL needleless syringe; may attach a nasal mucosal atomization device prior to delivering dose. Deliver half of the total dose volume into the first nare using the atomizer device or by dripping slowly into nostril, then deliver the other half of the dose into the second nare.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Do not mix with any liquid (such as grapefruit juice) prior to administration. Administer on empty stomach (feeding is usually contraindicated prior to sedation for procedures).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Parenteral:</b> Do <b>not</b> administer intraarterially.</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Administer undiluted deep IM into large muscle. The manufacturer’s labeling for Seizalam specifically recommends injection in the mid-outer thigh (vastus lateralis muscle).</p>
<p style="text-indent:-2em;margin-left:4em;">IV: For procedural sedation/anxiolysis/amnesia, administer by slow IV injection over at least 2 minutes using a concentration of 1 mg/mL or a dilution of the 1 or 5 mg/mL concentrations. For induction of anesthesia, administer IV bolus over 5 to 15 seconds (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Miller.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Miller.1'])">Ref</a></span>). For refractory status epilepticus, the loading dose is recommended to be infused slowly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27544138']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27544138'])">Ref</a></span>). For other clinical situations (eg, sedation in the mechanically ventilated patient), a continuous infusion may also be administered.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rectal:</b> Clinical trials utilized parenteral midazolam for rectal administration; administer a 1 to 5 mg/mL solution through a small, lubricated catheter or tube inserted rectally; hold buttocks closed for ~5 minutes after administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14578832','lexi-content-ref-11046209']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14578832','lexi-content-ref-11046209'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52613334"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Buccal: A buccal formulation is not currently available in the United States. Some trials used an injectable solution administered buccally (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16023510','lexi-content-ref-19114297']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16023510','lexi-content-ref-19114297'])">Ref</a></span>). International studies used a 10 mg/mL commercially available buccal formulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20554464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20554464'])">Ref</a></span>). Administer to the buccal mucosa between the gums and the cheek using an oral syringe; gently massage cheek; dose may be divided to both sides of the mouth (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20554464','lexi-content-ref-16023510']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20554464','lexi-content-ref-16023510'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Intranasal: The nasal spray formulation (Nayzilam) delivers a fixed dose of 5 mg and is not appropriate for all pediatric patients; for smaller intranasal doses, parenteral solution for injection product can be used; ensure appropriate product selection and administration technique.</p>
<p style="text-indent:-2em;margin-left:4em;">Nasal spray (Nayzilam): Product delivers a fixed dose and should only be used in Children ≥12 years and Adolescents: Do not test or prime before use; do not open blister packaging until ready to use. Administer 1 spray into 1 nostril; if a second dose is needed, administer in alternate nostril. A second dose should not be administered if the patient is having trouble breathing or experiencing excessive sedation.</p>
<p style="text-indent:-2em;margin-left:4em;">Parenteral solution for injection formulation: Administer using a mucosal atomizer (MAD nasal drug delivery device) or via needleless syringe. Administer half of the dose into each nostril. Maximum volume: 1 mL per nostril (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer on empty stomach (feeding is usually contraindicated prior to sedation for procedures).</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Vial for IV or IM administration only; premixed bag for IV administration only. Do not administer vial or premixed bag intra-arterially. Avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:4em;">IV (bolus, loading doses, intermittent therapy): Administer by slow IV injection over ≥2 to 5 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1959542','lexi-content-ref-1577053']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1959542','lexi-content-ref-1577053'])">Ref</a></span>). In adults: For induction of anesthesia, may administer IV push over 20 to 30 seconds per the manufacturer. For refractory status epilepticus, the loading dose is recommended to be infused at a rate of 2 mg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22528274']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22528274'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Neonates: Rapid administration (&lt;2 minutes) has been reported to cause severe hypotension especially if administered concurrently with fentanyl. For loading doses, administration over ≥1 hour has successfully prevented hypotension in neonates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10201714','lexi-content-ref-16164495']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10201714','lexi-content-ref-16164495'])">Ref</a></span>); however, administration over 2 to 5 minutes has also been described in mechanically ventilated patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1577053']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1577053'])">Ref</a></span>); manufacturer recommends against loading doses in neonates and suggests using a faster continuous infusion rate for the first several hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous IV infusion: Administer via an infusion pump.</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Administer undiluted deep IM into large muscle, generally into anterior-lateral aspect of thigh (vastus lateralis) in pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16048152','lexi-content-ref-2490015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16048152','lexi-content-ref-2490015'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Rectal: Clinical trials utilized parenteral midazolam for rectal administration; administer a 1 to 5 mg/mL solution through a small, lubricated catheter or tube inserted rectally; hold buttocks closed for ~5 minutes after administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14578832','lexi-content-ref-29805070','lexi-content-ref-11046209']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14578832','lexi-content-ref-29805070','lexi-content-ref-11046209'])">Ref</a></span>).</p></div>
<div class="block uica drugH1Div" id="F14472924"><span class="drugH1">Usual Infusion Concentrations: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Premixed solutions available.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV infusion:</b> 100 mg in 100 mL (concentration: 1 mg/mL) of D<sub>5</sub>W or NS.</p></div>
<div class="block uicp drugH1Div" id="F14472925"><span class="drugH1">Usual Infusion Concentrations: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Premixed solutions available (1 mg/mL).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV infusion:</b> 0.03 mg/mL, 0.5 mg/mL, 1 mg/mL, <b>or</b> 5 mg/mL.</p></div>
<div class="block meg drugH1Div" id="F53144875"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Nayzilam: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F211321s008lbl.pdf%23page%3D26&amp;token=F87%2B6XYB5uUR7rNoFnViNKwTdahG%2BSnbMcWd%2B41PAlNpSqsTXcnaFhi76K0quh0TXNJzIr580QpUfQ%2BMI6KuATf0alkU4sQN6zfQ0RYn5fEOeg5YSLjlUMSZQ%2B%2FX%2BVny&amp;TOPIC_ID=9650" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211321s008lbl.pdf#page=26</a></p></div>
<div class="block use drugH1Div" id="F196418"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>General anesthesia:</b> Induction of general anesthesia before administration of other anesthetic agents; maintenance of anesthesia as a component of balanced anesthesia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Mechanically ventilated patients in the ICU, sedation: </b>Sedation of intubated and mechanically ventilated patients as a component of anesthesia or during treatment in a critical care setting by continuous IV infusion.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Procedural sedation, outside the operating room:</b> Sedation, anxiolysis, and amnesia prior to or during diagnostic, therapeutic, or endoscopic procedures, or prior to surgery.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Seizures, intermittent: </b>Intranasal: Acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy ≥12 years of age.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Status epilepticus: </b>Treatment of status epilepticus in adults. <b>Note:</b> Only the injectable product Seizalam is FDA approved for the treatment of status epilepticus; however, any parenteral product approved for IM administration may be used off label for this indication.</p></div>
<div class="block off-label drugH1Div" id="F25730634"><span class="drugH1">Use: Off-Label: Adult</span><p>Agitation, acute/severe; Intoxication: Cocaine, methamphetamine, and other sympathomimetics; Palliative and end-of-life sedation; Rapid sequence intubation, outside the operating room; Status epilepticus (convulsive and nonconvulsive); Status epilepticus, refractory</p></div>
<div class="block mst drugH1Div" id="F196498"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Versed may be confused with VePesid, Vistaril</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (IV, oral administration for sedation in children) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Beers Criteria: Benzodiazepines (eg, midazolam) are identified in the Beers Criteria as potentially inappropriate medications to be avoided in patients 65 years and older because of risk of abuse, misuse, physical dependence, and addiction. In addition, older adults have increased risk of impaired cognition, delirium, falls, fractures, and motor vehicle accidents with benzodiazepine use; however, benzodiazepines may be appropriate in older adults when used for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine or ethanol withdrawal, severe generalized anxiety disorder, or periprocedural anesthesia (Beers Criteria [AGS 2023]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pediatric patients: High-risk medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">KIDs List: Midazolam, when used in very low birthweight neonates, is identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list; use should be avoided due to risk of severe intraventricular hemorrhage, periventricular leukomalacia, or death (strong recommendation; high quality of evidence) (PPA [Meyers 2020]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F196481"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2B6 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F196408"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antihepaciviral Combination Products: May increase the serum concentration of Midazolam. Management: Oral midazolam is contraindicated with antihepaciviral combination products. Avoid use with nasal midazolam. Consider alternatives to use with other routes of midazolam (IV, IM) when possible. Consider use of lower midazolam doses  if combined.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atorvastatin: May increase the serum concentration of Midazolam.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Benzodiazepines may enhance the adverse/toxic effect of CloZAPine.  Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine. Monitor for respiratory depression, hypotension, and other toxicities if these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobicistat: May increase the serum concentration of Midazolam. Management: Oral midazolam is contraindicated with cobicistat. Avoid use with nasal midazolam. Consider alternatives to use with other routes of midazolam (IV, IM) when possible. Consider use of lower midazolam doses  if combined.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Midazolam.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Midazolam.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Midazolam. Management: Avoid concomitant use of nasal midazolam and moderate CYP3A4 inhibitors. Consider alternatives to use with oral midazolam whenever possible and consider using lower midazolam doses. Monitor patients for sedation and respiratory depression if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Midazolam. Management: Avoid use of nasal midazolam and strong CYP3A4 inhibitors whenever possible, and consider alternatives to use with other routes of midazolam (oral, IV, IM). If combined, consider lower midazolam doses and monitor for increased midazolam toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Weak): May increase the serum concentration of Midazolam.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delavirdine: May increase the serum concentration of Midazolam.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ilaprazole: May increase the serum concentration of Benzodiazepines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: May increase the serum concentration of Midazolam. Management: Oral midazolam is contraindicated with, and for 2 weeks after, itraconazole. Avoid use with nasal midazolam. Consider alternatives to use with other routes of midazolam (IV, IM) when possible. Consider use of lower midazolam doses  if combined.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): May increase the serum concentration of Midazolam. Management: Oral midazolam is contraindicated with ketoconazole. Avoid use with nasal midazolam. Consider alternatives to use with other routes of midazolam (IV, IM) when possible. Consider use of lower midazolam doses  if combined.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Landiolol: Midazolam may enhance the therapeutic effect of Landiolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: May increase the serum concentration of Midazolam. Management: Combined use is contraindicated. For patients who must receive midazolam, discontinue lonafarnib for 10 to 14 days before and for 2 days after midazolam administration.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Melatonin: May enhance the sedative effect of Benzodiazepines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: Benzodiazepines may enhance the CNS depressant effect of Methadone.  Management: Clinicians should generally avoid concurrent use of methadone and benzodiazepines when possible; any combined use should be undertaken with extra caution.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: Benzodiazepines may enhance the adverse/toxic effect of OLANZapine.  Management: Monitor closely for hypotension, respiratory or central nervous system depression, and bradycardia if olanzapine is combined with benzodiazepines. Use of parenteral benzodiazepines with IM olanzapine is not recommended.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: Benzodiazepines may enhance the CNS depressant effect of Oxybate Salt Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Protease Inhibitors: May increase the serum concentration of Midazolam. Management: Oral midazolam is contraindicated with protease inhibitors. Avoid use with nasal midazolam. Consider alternatives to use with other routes of midazolam (IV, IM) when possible. Consider use of lower midazolam doses  if combined.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teduglutide: May increase the serum concentration of Benzodiazepines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: May diminish the therapeutic effect of Benzodiazepines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yohimbine: May diminish the therapeutic effect of Antianxiety Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F196439"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Oral: Grapefruit juice may increase serum concentrations of midazolam. Management: Avoid concurrent use of grapefruit juice with oral midazolam.</p></div>
<div class="block pri drugH1Div" id="F196425"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Midazolam crosses the placenta (Bach 1989; Kanto 1983).</p>
<p style="text-indent:0em;margin-top:2em;">In utero exposure to benzodiazepines has the potential to cause harm to the fetus. Teratogenic effects have been observed in some studies; however, a clear association has not been reported and additional data are needed (Bellantuono 2013; Freeman 2018; Grigoriadis 2019; Noh 2022; Szpunar 2022; Tinker 2019; Wikner 2007). Exposure to a benzodiazepine late in pregnancy may cause neonatal sedation (hypotonia, lethargy, respiratory depression) and/or symptoms of neonatal withdrawal (feeding difficulties, hyperreflexia, inconsolable crying, irritability, restlessness, tremors). Data related to long-term effects on neurodevelopment are inconclusive (Chen 2022; Radojčić 2017; Sundbakk 2022; Wang 2022). Newborns exposed to midazolam in utero should be monitored for feeding problems, respiratory depression, sedation, and withdrawal.</p>
<p style="text-indent:0em;margin-top:2em;">Based on animal data, repeated or prolonged use of general anesthetic and sedation medications that block N-methyl-D-aspartate (NMDA) receptors and/or potentiate gamma-aminobutyric acid (GABA) activity may affect brain development. Evaluate benefits and potential risks of fetal exposure to midazolam when duration of surgery is expected to be &gt;3 hours (Olutoye 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of midazolam may be altered (Hebert 2008; Wilson 1987). Midazolam use in obstetric anesthesia has been described (Frölich 2006; Heyman 1987; Kanto 1984; Neuman 2013; Senel 2014; Shergill 2012).</p>
<p style="text-indent:0em;margin-top:2em;">The ACOG recommends that pregnant patients should not be denied medically necessary surgery regardless of trimester. If the procedure is elective, it should be delayed until after delivery (ACOG 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Data related to the treatment of status epilepticus in pregnancy are limited; use of midazolam may be considered (NCS [Brophy 2012]; Rajiv 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to antiseizure medications is ongoing. Patients exposed to antiseizure medications during pregnancy are encouraged to enroll themselves in the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling 1-888-233-2334. Additional information is available at http://www.aedpregnancyregistry.org.</p></div>
<div class="block brc drugH1Div" id="F11229384"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Midazolam and hydroxymidazolam are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Data related to the presence of midazolam in breast milk is available following administration to 12 postpartum women for sleep. Breast milk and maternal serum were sampled in the morning, ~7 hours after the maternal dose. Following accidental administration of 2 oral doses (total dose: 30 mg) to 1 woman, breast milk concentrations of midazolam were 0.0001 mg/mL (30 nmol/L). Midazolam was not present in the breast milk of the 11 other patients (Matheson 1990).</p>
<p style="text-indent:-2em;margin-left:4em;">• Using a milk concentration of 0.0001 mg/mL (30 nmol/L), the estimated exposure to the breastfeeding infant would be 0.0015 mg/kg/day (relative infant dose [RID] 0.35% based on a weight-adjusted maternal dose of 30 mg).</p>
<p style="text-indent:-2em;margin-left:4em;">• In general, breastfeeding is considered acceptable when an RID of a medication is &lt;10% (Anderson 2016; Ito 2000).</p>
<p style="text-indent:-2em;margin-left:4em;">• In most reports, midazolam and hydroxymidazolam concentrations in breast milk are below the limit of quantification 4 hours after a single dose (Koitabashi 1997; Matheson 1990).</p>
<p style="text-indent:-2em;margin-left:2em;">CNS depression was reported in infants following exposure to benzodiazepines via breast milk (study included exposures to midazolam) (Kelly 2012); poor sucking may also occur.</p>
<p style="text-indent:-2em;margin-left:2em;">Breastfeeding during benzodiazepine therapy is not recommended due to the potential for drowsiness in the breastfeeding infant (Larsen 2015). According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. Infants exposed to oxazepam via breast milk should be monitored for feeding problems, respiratory depression, and poor weight gain.</p>
<p style="text-indent:-2em;margin-left:2em;">When used for sedation prior to a procedure, available guidelines suggest waiting for ≥4 hours after a maternal dose of midazolam to continue breastfeeding (Shergill 2012); some manufacturers suggest patients express and discard milk for 4 to 8 hours after midazolam administration to decrease potential exposure to a breastfed infant. The Academy of Breastfeeding Medicine recommends postponing elective surgery until milk supply and breastfeeding are established. Milk should be expressed ahead of surgery when possible. In general, when the child is healthy and full term, breastfeeding may resume, or milk may be expressed once the mother is awake and in recovery. For children who are at risk for apnea, hypotension, or hypotonia, milk may be saved for later use when the child is at lower risk (ABM [Reece-Stremtan 2017]). Small supplemental doses of midazolam used during cesarean delivery should not prevent breastfeeding once the mother is stable and alert (ABM [Martin 2018]).</p></div>
<div class="block dic drugH1Div" id="F196426"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Avoid grapefruit juice with oral syrup.</p></div>
<div class="block mop drugH1Div" id="F196412"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Level of sedation, respiratory rate, heart rate, blood pressure, oxygen saturation (ie, pulse oximetry).</p>
<p style="text-indent:-2em;margin-left:2em;">Critically ill patients: Assess and adjust sedation according to scoring system (eg, Richmond Agitation-Sedation Scale [RASS] or Sedation-Agitation Scale [SAS]) or clinical effect (eg, ventilator synchrony) (SCCM [Devlin 2018]).</p></div>
<div class="block pha drugH1Div" id="F196402"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Short-acting benzodiazepine (Griffin 2013). Binds to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron at several sites within the central nervous system, including the limbic system and reticular formation. Enhancement of the inhibitory effect of GABA on neuronal excitability results by increased neuronal membrane permeability to chloride ions. This shift in chloride ions results in hyperpolarization (a less excitable state) and stabilization. Benzodiazepine receptors and effects appear to be linked to the GABA-A receptors. Benzodiazepines do not bind to GABA-B receptors (Brunton 2011).</p></div>
<div class="block phk drugH1Div" id="F196421"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action:</p>
<p style="text-indent:-2em;margin-left:4em;">Sedation/anesthesia:</p>
<p style="text-indent:-2em;margin-left:6em;">IM: Children: Within 5 minutes; Adults: ~15 minutes.</p>
<p style="text-indent:-2em;margin-left:6em;">IV: 1 to 5 minutes (dose dependent) (Barr 2013; Horn 2004; Roberts 2019).</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: 10 to 20 minutes.</p>
<p style="text-indent:-2em;margin-left:6em;">Intranasal (nasal spray): Within 10 minutes.</p>
<p style="text-indent:-2em;margin-left:6em;">Intranasal (solution, injection): Children: 5.55 ± 2.22 minutes (Lee-Kim 2004); Adults: Within 5 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Peak effect: IM: Children: 15 to 30 minutes; Adults: 30 to 60 minutes; IV: 3 to 5 minutes; Intranasal (nasal spray): 30 minutes; Intranasal (solution, injection): Children: 10 minutes (al-Rakaf 2001).</p>
<p style="text-indent:-2em;margin-left:2em;">Duration:</p>
<p style="text-indent:-2em;margin-left:4em;">Classified as a short-acting benzodiazepine; classification based on benzodiazepines with half-life of 1 to 12 hours (Griffin 2013).</p>
<p style="text-indent:-2em;margin-left:4em;">Indication-specific durations:</p>
<p style="text-indent:-2em;margin-left:6em;">Sedation:</p>
<p style="text-indent:-2em;margin-left:8em;">Children: Intranasal (solution, injection): 23.1 minutes (Chiaretti 2011).</p>
<p style="text-indent:-2em;margin-left:8em;">Adults: IM: 20 to 120 minutes; IV: 7 to 75 minutes (Bell 1991).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: IM: Rapid, complete; Intranasal (nasal spray): Rapid; Oral, Intranasal (solution, injection): Rapid (Lee-Kim 2004).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Widely distributed in body including CSF; V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm infants (n=24; GA: 26 to 34 weeks; PNA: 3 to 11 days): IV: Median: 1.1 L/kg (range: 0.4 to 4.2 L/kg) (de Wildt 2001).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children 6 months to 16 years: IV: 1.24 to 2.02 L/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 1 to 3.1 L/kg; increased in females, elderly, and obesity.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~97%, primarily albumin; in patients with cirrhosis, protein binding is reduced with a free fraction of ~5% (Trouvin 1988).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively hepatic via CYP3A4; 60% to 70% of biotransformed midazolam is the active metabolite 1-hydroxy-midazolam (or alpha-hydroxymidazolam).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: 40% to 50% (Kanto 1985), ~36% (children); IM: &gt;90%; Intranasal (nasal spray): 44%; Intranasal (solution, injection): Children: ~60%; Rectal: Children: ~40% to 65% (mean: 52%) (Clausen 1988).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm infants (n=24; GA: 26 to 34 weeks; PNA: 3 to 11 days): IV: Median: 6.3 hours (range: 2.6 to 17.7 hours) (de Wildt 2001).</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates: 4 to 12 hours; seriously ill neonates: 6.5 to 12 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Children: IV: 2.9 to 4.5 hours; Syrup: 2.2 to 6.8 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 3 hours (range: 1.8 to 6.4 hours); IM: 4.2 ± 1.87 hours; Intranasal (nasal spray): 2.1 to 6.2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: IM: ~0.5 hours; Intranasal (nasal spray): Median 17.3 minutes (7.8 to 28.2 minutes); Oral: 0.17 to 2.65 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Intranasal (nasal spray): Urine (primarily as glucuronide conjugates of the hydroxylated metabolites); IV, IM: Urine (primarily as metabolites); Oral: Urine (~90% within 24 hours; primarily [60% to 70%] as glucuronide conjugates of the hydroxylated metabolites; &lt;0.03% as unchanged drug); feces (~2% to 10% over 5 days) (Kanto 1985; Smith 1981).</p>
<p style="text-indent:-2em;margin-left:2em;">Clearance:</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm infants (n=24; GA: 26 to 34 weeks; PNA: 3 to 11 days): Median: 1.8 mL/minute/kg (range: 0.7 to 6.7 mL/minute/kg) (de Wildt 2001).</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates &lt;39 weeks GA: 1.17 mL/minute/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates &gt;39 weeks GA: 1.84 mL/minute/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">Seriously ill neonates: 1.2 to 2 mL/minute/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants &gt;3 months of age: 9.1 mL/minute/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">Children &gt;1 year of age: 3.2 to 13.3 mL/minute/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">Healthy adults: 4.2 to 9 mL/minute/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults with acute renal failure: 1.9 mL/minute/kg.</p></div>
<div class="block phksp drugH1Div" id="F51159563"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Elimination half-life is prolonged and clearance is reduced. In patients with renal failure, reduced elimination of active hydroxylated metabolites leads to drug accumulation and prolonged sedation.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: In patients with cirrhosis, following oral administration, C<sub>max</sub> and bioavailability were 43% and 100% higher, and following IV administration clearance was reduced 50%, half-life increased 2.5-fold, and V<sub>d</sub> increased by 20%.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: IM, IV (mean age: 73 years): Plasma half-life was ~2-fold higher; mean V<sub>d</sub> increased consistently between 15% to 100%, and mean clearance decreased ~25%; Intranasal (nasal spray) (&gt;65 years of age): AUC and C<sub>max</sub> increased 21% to 45%.</p>
<p style="text-indent:-2em;margin-left:2em;">Heart failure: Following oral administration (7.5 mg), half-life increased 43%. Two-fold increase in the elimination half-life, a 25% decrease in the plasma clearance and a 40% increase in V<sub>d</sub> following parenteral administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Obesity: Mean half-life is prolonged (5.9 hours) and V<sub>d</sub> increased ~50%.</p>
<p style="text-indent:-2em;margin-left:2em;">Therapeutic hypothermia: Hypothermia may be associated with a 5-fold increase in plasma concentrations, likely due to decreased total body clearance (~11% decline in clearance for every centigrade decrease in body temperature below 36.5°C [97.7°F]) (Fukuoka 2004; Hostler 2010). During the rewarming phase, plasma concentrations decrease (~11% decline in plasma concentrations as temperature increases from 33°C to 37°C [91.4°F to 98.6°F]) (Bjelland 2014). The V<sub>d</sub> in hypothermia (core body temperature &lt;35°C [&lt;95°F]) may decrease ~45% during rewarming phase (Fukuoka 2004); however, some reports found no significant impact of hypothermia on total body clearance (Bastiaans 2013) or V<sub>d</sub> (Hostler 2010).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F196427"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Dormicum</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Dormicum | Dormonid | Midalan | Ormir | Rem chobet</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Dormicum | Midazolam mayrhofer</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Hypnovel</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Anquil | Benquil | Dormax | Dormicum | Dormitol | Hypnocum | Hypnofast | Midolam | Midzo | Milam | Mizolam</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Dormicum</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Dormicum</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Dormire | Dormium | Dormonid | Maleato de Midazolam | Midazolam | Prontomid</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Dormicum</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Dormonid | Noctura | Terap</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Dormicum | Li yue xi | Midazolam maleate</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Dormicum | Dormipron | Espatabs | Midazolam | Mizolam</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Dormicum | Midazolam accord</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Dormicum | Midazolam accord | Midazolam delta select</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Dormicum | Dormire</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Dormicum</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Dormicum</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Dormicum | Midathetic</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Dormicum</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Dormicum | Midazolam accord | Midazolam alpharma</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Midazolam</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Dormicum | Midazolam Rotexmedica</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Dormicum</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Dormicum | Midanxil</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Midolam</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Mezolam</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Dormicum</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Midafresa</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Dormicum</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Dormicum</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Dormicum</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Midazolam</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Dormicum</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Dormicum</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Dormicum</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Dormicum | Midazolam</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Domi | Dormicum | Fulsed | Midazolam</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Dormicum</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Dormicum</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Hypnovel | Midazolam</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Dormonid | Noctura</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Dormicum</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Cazolam | Dormicum | Hyrest | Milam</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Dormicum | Midazolam | Midazolam accord</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Midazolam HCL | Nayzilam | Versed</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Dormicum | Midazolam b. braun | Zolamid</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Dormicum | Midazolam dutriec | Midazolam icu vita | Noctura | Sedancor</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Dilemy | Dormicum | Dormicum (IV/IM/Rectal) | Hypnovel</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Dormicum</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Dormicum | Fulsed</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Midazolam accord</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Dormicum</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Dormicum</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Dormicum</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Dormicum</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Dormicum</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Dormicum | Uzolam</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Dormicum</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Dormicum | Dorminox | Hipnazolam | Midazolam</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Doricum</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Accord midazolam | Dormicum | Micro midazolam</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Dormicum</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11310461">
<a name="11310461"></a>Acworth JP, Purdie D, and Clark RC, "Intravenous Ketamine Plus Midazolam Is Superior to Intranasal Midazolam for Emergency Paediatric Procedural Sedation," <i>Emerg Med J</i>, 2001, 18(1):39-45.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/11310461/pubmed" id="11310461" target="_blank">11310461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20481651">
<a name="20481651"></a>Ahsman MJ, Hanekamp M, Wildschut ED, Tibboel D, Mathot RA. Population pharmacokinetics of midazolam and its metabolites during venoarterial extracorporeal membrane oxygenation in neonates. <i>Clin Pharmacokinet</i>. 2010;49(6):407-419. doi:10.2165/11319970-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/20481651/pubmed" id="20481651" target="_blank">20481651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28800805">
<a name="28800805"></a>Akerele E, Olupona T. Drugs of abuse. <i>Psychiatr Clin North Am</i>. 2017;40(3):501-517. doi:10.1016/j.psc.2017.05.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/28800805/pubmed" id="28800805" target="_blank">28800805</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32387007">
<a name="32387007"></a>Alansari K, Barkat M, Mohamed AH, Al Jawala SA, Othman SA. Intramuscular versus buccal midazolam for pediatric seizures: a randomized double-blinded trial. <i>Pediatr Neurol</i>. 2020;109:28-34. doi:10.1016/j.pediatrneurol.2020.03.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/32387007/pubmed" id="32387007" target="_blank">32387007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Allonen.1">
<a name="Allonen.1"></a>Allonen H, Ziegler, G, and Klotz U, “Midazolam Kinetics,” <i>Clin Pharmacol Ther</i>, 1981, 30(5):653-61.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11309871">
<a name="11309871"></a>al-Rakaf H, Bello LL, Turkustani A, et al, "Intra-Nasal Midazolam in Conscious Sedation of Young Paediatric Dental Patients," <i>Int J Paediatr Dent</i>, 2001, 11(1):33-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/11309871/pubmed" id="11309871" target="_blank">11309871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26810788">
<a name="26810788"></a>American Academy of Pediatrics (AAP) Committee on Fetus and Newborn and Section on Anesthesiology and Pain Medicine. Prevention and management of procedural pain in the neonate: an update. <i>Pediatrics</i>. 2016;137(2):e20154271. doi:10.1542/peds.2015-4271<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/26810788/pubmed" id="26810788" target="_blank">26810788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30913200">
<a name="30913200"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG committee opinion no. 775: nonobstetric surgery during pregnancy. <i>Obstet Gynecol</i>. 2019;133(4):e285-e286.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/30913200/pubmed" id="30913200" target="_blank">30913200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHP.1">
<a name="ASHP.1"></a>American Society of Health-System Pharmacists (ASHP). Pediatric continuous infusion standards. Available at https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/Pediatric-Infusion-Standards.ashx. Updated August 2022. Accessed April 21, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10201714">
<a name="10201714"></a>Anand KJ, Barton BA, McIntosh N, et al, "Analgesia and Sedation in Preterm Neonates Who Require Ventilatory Support: Results From the NOPAIN Trial. Neonatal Outcome and Prolonged Analgesia in Neonates," <i>Arch Pediatr Adolesc Med</i>, 1999, 153(4):331-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/10201714/pubmed" id="10201714" target="_blank">10201714</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30290021">
<a name="30290021"></a>Ancora G, Lago P, Garetti E, et al. Evidence-based clinical guidelines on analgesia and sedation in newborn infants undergoing assisted ventilation and endotracheal intubation. <i>Acta Paediatr</i>. 2019;108(2):208-217. doi:10.1111/apa.14606<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/30290021/pubmed" id="30290021" target="_blank">30290021</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20554464">
<a name="20554464"></a>Ashrafi MR, Khosroshahi N, Karimi P, et al. Efficacy and usability of buccal midazolam in controlling acute prolonged convulsive seizures in children. <i>Eur J Paediatr Neurol</i>. 2010;14(5):434-438. doi: 10.1016/j.ejpn.2010.05.009.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/20554464/pubmed" id="20554464" target="_blank">20554464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2919760">
<a name="2919760"></a>Bach V, Carl P, Ravlo O, et al. A randomized comparison between midazolam and thiopental for elective cesarean section anesthesia: III. Placental transfer and elimination in neonates. <i>Anesth Analg</i>. 1989;68(3):238-242.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/2919760/pubmed" id="2919760" target="_blank">2919760</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28259526">
<a name="28259526"></a>Bailey AM, Baum RA, Horn K, et al. Review of intranasally administered medications for use in the emergency department. <i>J Emerg Med</i>. 2017;53(1):38-48. doi:10.1016/j.jemermed.2017.01.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/28259526/pubmed" id="28259526" target="_blank">28259526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23269131">
<a name="23269131"></a>Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. <i>Crit Care Med.</i> 2013;41(1):263-306. doi:10.1097/CCM.0b013e3182783b72<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/23269131/pubmed" id="23269131" target="_blank">23269131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23192725">
<a name="23192725"></a>Bastiaans DE, Swart EL, van Akkeren JP, Derijks LJ. Pharmacokinetics of midazolam in resuscitated patients treated with moderate hypothermia. <i>Int J Clin Pharm</i>. 2013;35(2):210-216. doi:10.1007/s11096-012-9725-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/23192725/pubmed" id="23192725" target="_blank">23192725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7603229">
<a name="7603229"></a>Bauer TM, Ritz R, Haberthür C, et al. Prolonged sedation due to accumulation of conjugated metabolites of midazolam. <i>Lancet</i>. 1995;346(8968):145-147. doi:10.1016/s0140-6736(95)91209-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/7603229/pubmed" id="7603229" target="_blank">7603229</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1817958">
<a name="1817958"></a>Bell DM, Richards G, Dhillon S, et al. A comparative pharmacokinetic study of intravenous and intramuscular midazolam in patients with epilepsy. <i>Epilepsy</i>
<i>Res</i>. 1991;10(2-3):183-190. doi:10.1016/0920-1211(91)90011-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/1817958/pubmed" id="1817958" target="_blank">1817958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23044244">
<a name="23044244"></a>Bellantuono C, Tofani S, Di Sciascio G, Santone G. Benzodiazepine exposure in pregnancy and risk of major malformations: a critical overview. <i>Gen Hosp Psychiatry</i>. 2013;35(1):3-8. doi:10.1016/j.genhosppsych.2012.09.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/23044244/pubmed" id="23044244" target="_blank">23044244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16647994">
<a name="16647994"></a>Bhattacharyya M, Kalra V, and Gulati S, "Intranasal Midazolam vs Rectal Diazepam in Acute Childhood Seizures," <i>Pediatr Neurol</i>, 2006, 34(5):355-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/16647994/pubmed" id="16647994" target="_blank">16647994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24611449">
<a name="24611449"></a>Bjelland TW, Klepstad P, Haugen BO, Nilsen T, Salvesen O, Dale O. Concentrations of remifentanil, propofol, fentanyl, and midazolam during rewarming from therapeutic hypothermia. <i>Acta Anaesthesiol Scand</i>. 2014;58(6):709-715. doi:10.1111/aas.12300<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/24611449/pubmed" id="24611449" target="_blank">24611449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11549100">
<a name="11549100"></a>Bolon M, Bastien O, Flamens C, Paulus S, Boulieu R. Midazolam disposition in patients undergoing continuous venovenous hemodialysis.<i> J Clin Pharmacol.</i> 2001;41(9):959-962. doi:10.1177/00912700122010933<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/11549100/pubmed" id="11549100" target="_blank">11549100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2384705">
<a name="2384705"></a>Bottomley DM, Hanks GW. Subcutaneous midazolam infusion in palliative care. <i>J Pain Symptom Manage</i>. 1990;5(4):259-261. doi:10.1016/0885-3924(90)90020-k<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/2384705/pubmed" id="2384705" target="_blank">2384705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Boyer.1">
<a name="Boyer.1"></a>Boyer EW, Seifert SA, Hernon C. Methamphetamine: acute intoxication. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 28, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14872039">
<a name="14872039"></a>Boylan GB, Rennie JM, Chorley G, et al, "Second-Line Anticonvulsant Treatment of Neonatal Seizures: A Video-EEG Monitoring Study," <i>Neurology</i>, 2004, 62(3):486-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/14872039/pubmed" id="14872039" target="_blank">14872039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17479023">
<a name="17479023"></a>Bozkurt P, "Premedication of the Pediatric Patient - Anesthesia for the Uncooperative Child," <i>Curr Opin Anaesthesiol</i>, 2007, 20(3):211-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/17479023/pubmed" id="17479023" target="_blank">17479023</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bravenec.1">
<a name="Bravenec.1"></a>Bravenec B. General anesthesia: intravenous induction agents. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 4, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25141974">
<a name="25141974"></a>Brill MJ, van Rongen A, Houwink AP, et al. Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: a comparison with healthy volunteers. <i>Clin Pharmacokinet</i>. 2014;53(10):931-941. doi:10.1007/s40262-014-0166-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/25141974/pubmed" id="25141974" target="_blank">25141974</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22528274">
<a name="22528274"></a>Brophy GM, Bell R, Claassen J, et al; Neurocritical Care Society Status Epilepticus Guideline Writing Committee. Guidelines for the evaluation and management of status epilepticus. <i>Neurocrit Care</i>. 2012;17(1):3-23. doi:10.1007/s12028-012-9695-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/22528274/pubmed" id="22528274" target="_blank">22528274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Brunton.1">
<a name="Brunton.1"></a>Brunton LL, Chabner BA, Knollmann BC, eds. <i>Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics</i>. 12th ed. New York, NY: McGraw-Hill Medical; 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30144232">
<a name="30144232"></a>Bua J, Massaro M, Cossovel F, et al. Intranasal dexmedetomidine, as midazolam-sparing drug, for MRI in preterm neonates. <i>Paediatr Anaesth</i>. 2018;28(8):747-748. doi:10.1111/pan.13454<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/30144232/pubmed" id="30144232" target="_blank">30144232</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bystritsky.1">
<a name="Bystritsky.1"></a>Bystritsky A. Pharmacotherapy for generalized anxiety disorder in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 2, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Caro.1">
<a name="Caro.1"></a>Caro D. Induction agents for rapid sequence intubation in adults for emergency medicine and critical care. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 20, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15753426">
<a name="15753426"></a>Castro Conde JR, Hernández Borges AA, Doménech Martínez E, et al, "Midazolam in Neonatal Seizures With No Response to Phenobarbital," <i>Neurology</i>, 2005, 64(5):876-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/15753426/pubmed" id="15753426" target="_blank">15753426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9127414">
<a name="9127414"></a>Chamberlain JM, Altieri AM, Futterman C, Young GM, Ochsenschlager DW, Waisman Y. A prospective, randomized study comparing intramuscular midazolam with intravenous diazepam for the treatment of seizures in children. <i>Pediatr Emerg Care</i>. 1997;13(2):92-94.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/9127414/pubmed" id="9127414" target="_blank">9127414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36413366">
<a name="36413366"></a>Chen VC, Wu SI, Lin CF, Lu ML, Chen YL, Stewart R. Association of prenatal exposure to benzodiazepines with development of autism spectrum and attention-deficit/hyperactivity disorders. <i>JAMA Netw Open</i>. 2022;5(11):e2243282. doi:10.1001/jamanetworkopen.2022.43282<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/36413366/pubmed" id="36413366" target="_blank">36413366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cherny.1">
<a name="Cherny.1"></a>Cherny N. Palliative sedation. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 23, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25210083">
<a name="25210083"></a>Cherny NI; ESMO Guidelines Working Group. ESMO clinical practice guidelines for the management of refractory symptoms at the end of life and the use of palliative sedation. <i>Ann Oncol</i>. 2014;25(suppl 3):iii143-iii1152.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/25210083/pubmed" id="25210083" target="_blank">25210083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21030365">
<a name="21030365"></a>Chiaretti A, Barone G, Rigante D, et al, "Intranasal Lidocaine and Midazolam for Procedural Sedation in Children," <i>Arch Dis Child</i>, 2011, 96(2):160-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/21030365/pubmed" id="21030365" target="_blank">21030365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11571331">
<a name="11571331"></a>Claassen J, Hirsch LJ, Emerson RG, Bates JE, Thompson TB, Mayer SA. Continuous EEG monitoring and midazolam infusion for refractory nonconvulsive status epilepticus. <i>Neurology</i>. 2001;57(6):1036-1042.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/11571331/pubmed" id="11571331" target="_blank">11571331</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3382589">
<a name="3382589"></a>Clausen TG, Wolff J, Hansen PB, et al. Pharmacokinetics of midazolam and alpha-hydroxy-midazolam following rectal and intravenous administration. <i>Br J Clin Pharmacol</i>. 1988;25(4):457-463.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/3382589/pubmed" id="3382589" target="_blank">3382589</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25602358">
<a name="25602358"></a>Curley MA, Wypij D, Watson RS, et al. Protocolized sedation vs usual care in pediatric patients mechanically ventilated for acute respiratory failure: a randomized clinical trial. <i>JAMA</i>. 2015;313(4):379-389. doi:10.1001/jama.2014.18399<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/25602358/pubmed" id="25602358" target="_blank">25602358</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Delgado.1">
<a name="Delgado.1"></a>Delgado J. Intoxication from LSD and other common hallucinogens. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 28, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30113379">
<a name="30113379"></a>Devlin JW, Skrobik Y, Gélinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. <i>Crit Care Med</i>. 2018;46(9):e825-e873. doi:10.1097/CCM.0000000000003299<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/30113379/pubmed" id="30113379" target="_blank">30113379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11753268">
<a name="11753268"></a>de Wildt SN, Kearns GL, Hop WC, et al. Pharmacokinetics and metabolism of intravenous midazolam in preterm infants. <i>Clin Pharmacol Ther</i>. 2001;70(6):525-531.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/11753268/pubmed" id="11753268" target="_blank">11753268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Drislane.1">
<a name="Drislane.1"></a>Drislane FW. Convulsive status epilepticus in adults: Management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 22, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Drislane.1">
<a name="Drislane.1"></a>Drislane FW. Refractory status epilepticus in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 22, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37196592">
<a name="37196592"></a>Engstrom K, Brown CS, Mattson AE, Lyons N, Rech MA. Pharmacotherapy optimization for rapid sequence intubation in the emergency department. <i>Am J Emerg Med</i>. 2023;70:19-29. doi:10.1016/j.ajem.2023.05.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/37196592/pubmed" id="37196592" target="_blank">37196592</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32513237">
<a name="32513237"></a>Erstad BL, Barletta JF. Drug dosing in the critically ill obese patient-a focus on sedation, analgesia, and delirium. <i>Crit Care</i>. 2020;24(1):315. doi:10.1186/s13054-020-03040-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/32513237/pubmed" id="32513237" target="_blank">32513237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOO">
<a name="Expert.DOO"></a>Expert opinion. Senior Obesity Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29364490">
<a name="29364490"></a>Fantacci C, Fabrizio GC, Ferrara P, Franceschi F, Chiaretti A. Intranasal drug administration for procedural sedation in children admitted to pediatric emergency room. <i>Eur Rev Med Pharmacol Sci</i>. 2018;22(1):217-222. doi:10.26355/eurrev_201801_14120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/29364490/pubmed" id="29364490" target="_blank">29364490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31256150">
<a name="31256150"></a>Favié LMA, Groenendaal F, van den Broek MPH, et al. Phenobarbital, midazolam pharmacokinetics, effectiveness, and drug-drug interaction in asphyxiated neonates undergoing therapeutic hypothermia. <i>Neonatology</i>. 2019;116(2):154-162. doi:10.1159/000499330<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/31256150/pubmed" id="31256150" target="_blank">31256150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24363133">
<a name="24363133"></a>Fernandez A, Lantigua H, Lesch C, et al. High-dose midazolam infusion for refractory status epilepticus. <i>Neurology</i>. 2014;82(4):359-365. doi:10.1212/WNL.0000000000000054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/24363133/pubmed" id="24363133" target="_blank">24363133</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11198507">
<a name="11198507"></a>Fişgin T, Gürer Y, Senbil N, et al, "Nasal Midazolam Effects on Childhood Acute Seizures," <i>J Child Neurol</i>, 2000, 15(12):833-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/11198507/pubmed" id="11198507" target="_blank">11198507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11952072">
<a name="11952072"></a>Fişgin T, Gurer Y, Teziç T, et al, "Effects of Intranasal Midazolam and Rectal Diazepam on Acute Convulsions in Children: Prospective Randomized Study," <i>J Child Neurol</i>, 2002, 17(2):123-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/11952072/pubmed" id="11952072" target="_blank">11952072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9220206">
<a name="9220206"></a>Fragen RJ, “Pharmacokinetics and Pharmacodynamics of Midazolam Given via Continuous Intravenous Infusion in Intensive Care Units,” <i>Clin Ther</i>, 1997, 19(3):405-19.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/9220206/pubmed" id="9220206" target="_blank">9220206</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Frank.1">
<a name="Frank.1"></a>Frank RL. Procedural sedation in adults: Medication selection, dosing, and discharge criteria. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 3, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29958100">
<a name="29958100"></a>Freeman MP, Góez-Mogollón L, McInerney KA, et al. Obstetrical and neonatal outcomes after benzodiazepine exposure during pregnancy: results from a prospective registry of women with psychiatric disorders. <i>Gen Hosp Psychiatry</i>. 2018;53:73-79. doi:10.1016/j.genhosppsych.2018.05.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/29958100/pubmed" id="29958100" target="_blank">29958100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16371613">
<a name="16371613"></a>Frölich MA, Burchfield DJ, Euliano TY, Caton D. A single dose of fentanyl and midazolam prior to Cesarean section have no adverse neonatal effects. <i>Can J Anaesth</i>. 2006;53(1):79-85.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/16371613/pubmed" id="16371613" target="_blank">16371613</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15036742">
<a name="15036742"></a>Fukuoka N, Aibiki M, Tsukamoto T, Seki K, Morita S. Biphasic concentration change during continuous midazolam administration in brain-injured patients undergoing therapeutic moderate hypothermia. <i>Resuscitation</i>. 2004;60(2):225-230. doi:10.1016/j.resuscitation.2003.09.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/15036742/pubmed" id="15036742" target="_blank">15036742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26912127">
<a name="26912127"></a>Garriga M, Pacchiarotti I, Kasper S, et al. Assessment and management of agitation in psychiatry: expert consensus. <i>World J Biol Psychiatry</i>. 2016;17(2):86-128. doi:10.3109/15622975.2015.1132007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/26912127/pubmed" id="26912127" target="_blank">26912127</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26900382">
<a name="26900382"></a>Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. <i>Epilepsy Curr</i>. 2016;16(1):48-61. doi:10.5698/1535-7597-16.1.48<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/26900382/pubmed" id="26900382" target="_blank">26900382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6742481">
<a name="6742481"></a>Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, Shader RI. Effect of age, gender, and obesity on midazolam kinetics. <i>Anesthesiology</i>. 1984;61(1):27-35.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/6742481/pubmed" id="6742481" target="_blank">6742481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23789008">
<a name="23789008"></a>Griffin CE 3rd, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system-mediated effects. <i>Ochsner J</i>. 2013;13(2):214-223.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/23789008/pubmed" id="23789008" target="_blank">23789008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31294935">
<a name="31294935"></a>Grigoriadis S, Graves L, Peer M, et al. Benzodiazepine use during pregnancy alone or in combination with an antidepressant and congenital malformations: systematic review and meta-analysis. <i>J Clin Psychiatry</i>. 2019;80(4):18r12412. doi:10.4088/JCP.18r1241<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/31294935/pubmed" id="31294935" target="_blank">31294935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Miller.1">
<a name="Miller.1"></a>Gropper MA, Cohen NH, Eriksson LI, Fleisher LA, Leslie K, Wiener-Kronish JP. <i>Miller’s Anesthesia.</i> 9th ed. Elsevier; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29413725">
<a name="29413725"></a>Groth CM, Acquisto NM, Khadem T. Current practices and safety of medication use during rapid sequence intubation. <i>J Crit Care</i>. 2018;45:65-70. doi:10.1016/j.jcrc.2018.01.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/29413725/pubmed" id="29413725" target="_blank">29413725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hansen.1">
<a name="Hansen.1"></a>Hansen AR, Stark AR, Eichenwald EC, Martin CR. Appendix B: Intubation Sedation Guidelines. In: Hansen AR, Stark AR, Eichenwald EC, Martin CR, eds. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 9th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7567258">
<a name="7567258"></a>Harcke HT, Grissom LE, and Meister MA, "Sedation in Pediatric Imaging Using Intranasal Midazolam," <i>Pediatr Radiol</i>, 1995, 25(5):341-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/7567258/pubmed" id="7567258" target="_blank">7567258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188867">
<a name="19188867"></a>Hartman ME, McCrory DC, and Schulman SR, “Efficacy of Sedation Regimens to Facilitate Mechanical Ventilation in the Pediatric Intensive Care Unit: A Systematic Review,” <i>Pediatr Crit Care Med</i>, 2009, 10(2):246-55.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/19188867/pubmed" id="19188867" target="_blank">19188867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1959542">
<a name="1959542"></a>Hartwig S, Roth B, Theisohn M. Clinical experience with continuous intravenous sedation using midazolam and fentanyl in the paediatric intensive care unit. <i>Eur J Pediatr</i>. 1991;150(11):784-788. doi:10.1007/BF02026712<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/1959542/pubmed" id="1959542" target="_blank">1959542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18288078">
<a name="18288078"></a>Hebert MF, Easterling TR, Kirby B, et al. Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. <i>Clin Pharmacol Ther</i>. 2008;84(2):248-253.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/18288078/pubmed" id="18288078" target="_blank">18288078</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Heyman.1">
<a name="Heyman.1"></a>Heyman HJ and Salem MR. Is midazolam desirable for sedation in parturients? Reply. <i>Anesthesiology</i>. 1987;66(4):577.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hoffman.1">
<a name="Hoffman.1"></a>Hoffman RS. Internal concealment of drugs of abuse (body packing). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 12, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20679166">
<a name="20679166"></a>Holsti M, Dudley N, Schunk J, et al, "Intranasal Midazolam vs Rectal Diazepam for the Home Treatment of Acute Seizures in Pediatric Patients With Epilepsy," <i>Arch Pediatr Adolesc Med</i>, 2010, 164(8):747-53.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/20679166/pubmed" id="20679166" target="_blank">20679166</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17413428">
<a name="17413428"></a>Holsti M, Sill BL, Firth SD, et al. Prehospital Intranasal Midazolam for the Treatment of Pediatric Seizures. <i>Pediatr Emerg Care</i>. 2007;23(3):148-153.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/17413428/pubmed" id="17413428" target="_blank">17413428</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15121142">
<a name="15121142"></a>Horn E, Nesbit SA. Pharmacology and pharmacokinetics of sedatives and analgesics. <i>Gastrointest Endosc Clin N Am</i>. 2004;14(2):247-268. doi:10.1016/j.giec.2004.01.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/15121142/pubmed" id="15121142" target="_blank">15121142</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20164112">
<a name="20164112"></a>Hostler D, Zhou J, Tortorici MA, et al. Mild hypothermia alters midazolam pharmacokinetics in normal healthy volunteers. <i>Drug Metab Dispos</i>. 2010;38(5):781-788. doi:10.1124/dmd.109.031377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/20164112/pubmed" id="20164112" target="_blank">20164112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11773648">
<a name="11773648"></a>Iqbal MM, Sobhan T, Ryals T, et al, "Effects of Commonly Used Benzodiazepines on the Fetus, the Neonate, and the Nursing Infant," <i>Psychiatr Serv</i>, 2002, 53(1):39-49.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/11773648/pubmed" id="11773648" target="_blank">11773648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1577053">
<a name="1577053"></a>Jacqz-Aigrain E, Daoud P, Burtin P, et al, "Pharmacokinetics of Midazolam During Continuous Infusion in Critically Ill Neonates," <i>Eur J Clin Pharmacol</i>, 1992, 42(3):329-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/1577053/pubmed" id="1577053" target="_blank">1577053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7915348">
<a name="7915348"></a>Jacqz-Aigrain E, Daoud P, Burtin P, et al, “Placebo-Controlled Trial of Midazolam Sedation in Mechanically Ventilated Newborn Babies,” <i>Lancet</i>, 1994, 344(8923):646-50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/7915348/pubmed" id="7915348" target="_blank">7915348</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26342397">
<a name="26342397"></a>Jennum P, Baandrup L, Ibsen R, et al. Increased all-cause mortality with use of psychotropic medication in dementia patients and controls: A population-based register study. <i>Eur Neuropsychopharmacol.</i> 2015;25(11):1906-1913. doi: 10.1016/j.euroneuro.2015.08.014.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/26342397/pubmed" id="26342397" target="_blank">26342397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20557707">
<a name="20557707"></a>Johnson E, Briskie D, Majewski R, et al, "The Physiologic and Behavioral Effects of Oral and Intranasal Midazolam in Pediatric Dental Patients," <i>Pediatr Dent</i>, 2010, 32(3):229-38.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/20557707/pubmed" id="20557707" target="_blank">20557707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Joshi.1">
<a name="Joshi.1"></a>Joshi GP. Anesthetic management for enhanced recovery after major surgery (ERAS) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 21, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jooste.1">
<a name="Jooste.1"></a>Jooste E. Anesthesia for adults with congenital heart disease undergoing noncardiac surgery. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 25, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14578832">
<a name="14578832"></a>Kanegaye JT, Favela JL, Acosta M, Bank DE. High-dose rectal midazolam for pediatric procedures: a randomized trial of sedative efficacy and agitation. <i>Pediatr Emerg Care</i>. 2003;19(5):329-336.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/14578832/pubmed" id="14578832" target="_blank">14578832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3161005">
<a name="3161005"></a>Kanto J. Midazolam: the first water-soluble benzodiazepine-pharmacology, pharmacokinetics and efficacy in insomnia and anesthesia. <i>Pharmacotherapy.</i> 1985;5(3):138-155.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/3161005/pubmed" id="3161005" target="_blank">3161005</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6711257">
<a name="6711257"></a>Kanto J, Aaltonen L, Erkkola R, Aärimaa L. Pharmacokinetics and sedative effect of midazolam in connection with caesarean section performed under epidural analgesia.<i> Acta Anaesthesiol Scand</i>. 1984;28(1):116-118.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/6711257/pubmed" id="6711257" target="_blank">6711257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6851409">
<a name="6851409"></a>Kanto J, Sjövall S, Erkkola R, Himberg JJ, Kangas L. Placental transfer and maternal midazolam kinetics. <i>Clin Pharmacol Ther</i>. 1983;33(6):786-791. doi:10.1038/clpt.1983.107<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/6851409/pubmed" id="6851409" target="_blank">6851409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21817086">
<a name="21817086"></a>Karlage K, Earhart Z, Green-Boesen K, Myrdal PB. Stability of midazolam hydrochloride injection 1-mg/mL solutions in polyvinyl chloride and polyolefin bags. <i>Am J Health Syst Pharm</i>. 2011;68(16):1537-1540.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/21817086/pubmed" id="21817086" target="_blank">21817086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31682078">
<a name="31682078"></a>Kay L, Merkel N, von Blomberg A, et al. Intranasal midazolam as first-line inhospital treatment for status epilepticus: a pharmaco-EEG cohort study. <i>Ann Clin Transl Neurol</i>. 2019;6(12):2413-2425. doi:10.1002/acn3.50932<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/31682078/pubmed" id="31682078" target="_blank">31682078</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22504099">
<a name="22504099"></a>Kelly LE, Poon S, Madadi P, Koren G. Neonatal benzodiazepines exposure during breastfeeding. <i>J Pediatr</i>. 2012;161(3):448-451.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/22504099/pubmed" id="22504099" target="_blank">22504099</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29885904">
<a name="29885904"></a>Klein LR, Driver BE, Miner JR, et al. Intramuscular midazolam, olanzapine, ziprasidone, or haloperidol for treating acute agitation in the emergency department. <i>Ann Emerg Med</i>. 2018;72(4):374-385. doi:10.1016/j.annemergmed.2018.04.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/29885904/pubmed" id="29885904" target="_blank">29885904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16387219">
<a name="16387219"></a>Knott JC, Taylor DM, Castle DJ. Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. <i>Ann Emerg Med</i>. 2006;47(1):61-67. doi:10.1016/j.annemergmed.2005.07.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/16387219/pubmed" id="16387219" target="_blank">16387219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28921122">
<a name="28921122"></a>Koitabashi T, Satoh N, Takino Y. Intravenous midazolam passage into breast milk. <i>J Anesth</i>. 1997;11(3):242-243. doi:10.1007/BF02480048<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/28921122/pubmed" id="28921122" target="_blank">28921122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16517277">
<a name="16517277"></a>Krauss B, Green SM. Procedural sedation and analgesia in children. <i>Lancet</i>. 2006;367(9512):766-780.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/16517277/pubmed" id="16517277" target="_blank">16517277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10816184">
<a name="10816184"></a>Kress JP, Pohlman AS, O'Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. <i>N Engl J Med</i>. 2000;342(20):1471-1477. doi:10.1056/NEJM200005183422002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/10816184/pubmed" id="10816184" target="_blank">10816184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30562908">
<a name="30562908"></a>Ku LC, Simmons C, Smith PB, et al. Intranasal midazolam and fentanyl for procedural sedation and analgesia in infants in the neonatal intensive care unit. <i>J Neonatal Perinatal Med</i>. 2019;12(2):143-148. doi:10.3233/NPM-17149<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/30562908/pubmed" id="30562908" target="_blank">30562908</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1559361">
<a name="1559361"></a>Kumar A, Bleck TP. Intravenous midazolam for the treatment of refractory status epilepticus. <i>Crit Care Med</i>. 1992;20(4):483-488.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/1559361/pubmed" id="1559361" target="_blank">1559361</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20176672">
<a name="20176672"></a>Kumar P, Denson SE, Mancuso TJ, et al. Clinical report—Premedication for nonemergency endotracheal intubation in the neonate. <i>Pediatrics</i>. 2010;125(3):608-615.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/20176672/pubmed" id="20176672" target="_blank">20176672</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12767460">
<a name="12767460"></a>Kutlu NO, Dogrul M, Yakinci C, Soylu H. Buccal midazolam for treatment of prolonged seizures in children. <i>Brain Dev</i>. 2003;25(4):275-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/12767460/pubmed" id="12767460" target="_blank">12767460</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11042416">
<a name="11042416"></a>Kutlu NO, Yakinci C, Dogrul M, et al, "Intranasal Midazolam for Prolonged Convulsive Seizures," <i>Brain Dev</i>, 2000, 22(6):359-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/11042416/pubmed" id="11042416" target="_blank">11042416</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21714826">
<a name="21714826"></a>Lader M. Benzodiazepines revisited--will we ever learn? <i>Addiction</i>. 2011;106(12):2086-2109. doi:10.1111/j.1360-0443.2011.03563.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/21714826/pubmed" id="21714826" target="_blank">21714826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29805070">
<a name="29805070"></a>Lam SHF, Li DR, Hong CE, Vilke GM. Systematic review: rectal administration of medications for pediatric procedural sedation. <i>J Emerg Med</i>. 2018;55(1):51-63. doi:10.1016/j.jemermed.2018.04.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/29805070/pubmed" id="29805070" target="_blank">29805070</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16048152">
<a name="16048152"></a>Lam C, Udin RD, Malamed SF, et al, "Midazolam Premedication in Children: A Pilot Study Comparing Intramuscular and Intranasal Administration," <i>Anesth Prog</i>, 2005, 52(2):56-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/16048152/pubmed" id="16048152" target="_blank">16048152</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18496113">
<a name="18496113"></a>Lane RD and Schunk JE, "Atomized Intranasal Midazolam Use for Minor Procedures in the Pediatric Emergency Department," <i>Pediatr Emerg Care</i>, 2008, 24(5):300-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/18496113/pubmed" id="18496113" target="_blank">18496113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26344706">
<a name="26344706"></a>Larsen ER, Damkier P, Pedersen LH, et al; Danish Psychiatric Society; Danish Society of Obstetrics and Gynecology; Danish Paediatric Society; Danish Society of Clinical Pharmacology. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28. doi:10.1111/acps.12479<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/26344706/pubmed" id="26344706" target="_blank">26344706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15587094">
<a name="15587094"></a>Lee-Kim SJ, Fadavi S, Punwani I, et al, "Nasal Versus Oral Midazolam Sedation for Pediatric Dental Patients," <i>J Dent Child (Chic)</i>, 2004, 71(2):126-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/15587094/pubmed" id="15587094" target="_blank">15587094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27544138">
<a name="27544138"></a>Legriel S, Oddo M, Brophy GM. What's new in refractory status epilepticus? <i>Intensive Care Med</i>. 2017;43(4):543-546. doi:10.1007/s00134-016-4501-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/27544138/pubmed" id="27544138" target="_blank">27544138</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8414846">
<a name="8414846"></a>Lugo RA, Fishbein M, Nahata MC, et al, “Complication of Intranasal Midazolam,” <i>Pediatrics</i>, 1993, 92(4):638.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/8414846/pubmed" id="8414846" target="_blank">8414846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2936661">
<a name="2936661"></a>MacGilchrist AJ, Birnie GG, Cook A, et al. Pharmacokinetics and pharmacodynamics of intravenous midazolam in patients with severe alcoholic cirrhosis. <i>Gut.</i> 1986;27(2):190-195.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/2936661/pubmed" id="2936661" target="_blank">2936661</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2490015">
<a name="2490015"></a>Malamed SF, Quinn CL, and Hatch HG, "Pediatric Sedation With Intramuscular and Intravenous Midazolam," <i>Anesth Prog</i>, 1989, 36(4-5):155-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/2490015/pubmed" id="2490015" target="_blank">2490015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15460178">
<a name="15460178"></a>Mancuso CE, Tanzi MG, Gabay M. Paradoxical reactions to benzodiazepines: literature review and treatment options. <i>Pharmacotherapy</i>. 2004;24(9):1177-1185.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/15460178/pubmed" id="15460178" target="_blank">15460178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29595994">
<a name="29595994"></a>Martin E, Vickers B, Landau R, Reece-Stremtan S. ABM clinical protocol #28, peripartum analgesia and anesthesia for the breastfeeding mother. <i>Breastfeed Med</i>. 2018;13(3):164-171.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/29595994/pubmed" id="29595994" target="_blank">29595994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25854310">
<a name="25854310"></a>Masman AD, van Dijk M, Tibboel D, Baar FP, Mathôt RA. Medication use during end-of-life care in a palliative care centre. <i>Int J Clin Pharm</i>. 2015;37(5):767-775. doi:10.1007/s11096-015-0094-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/25854310/pubmed" id="25854310" target="_blank">25854310</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9415834">
<a name="9415834"></a>Massanari M, Novitsky J, and Reinstein LJ, “Paradoxical Reactions in Children Associated With Midazolam Use During Endoscopy,” <i>Clin Pediatr (Phila)</i>, 1997, 36(12):681-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/9415834/pubmed" id="9415834" target="_blank">9415834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2288825">
<a name="2288825"></a>Matheson I, Lunde PK, Bredesen JE. Midazolam and nitrazepam in the maternity ward: milk concentrations and clinical effects. <i>Br J Clin Pharmacol</i>. 1990;30(6):787-793. doi:10.1111/j.1365-2125.1990.tb05443.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/2288825/pubmed" id="2288825" target="_blank">2288825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33089024">
<a name="33089024"></a>Mayel M, Nejad MA, Khabaz MS, Bazrafshani MS, Mohajeri E. Intranasal midazolam sedation as an effective sedation route in pediatric patients for radiologic imaging in the emergency ward: A single-blind randomized trial. <i>Turk J Emerg Med</i>. 2020;20(4):168-174. doi:10.4103/2452-2473.297461<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/33089024/pubmed" id="33089024" target="_blank">33089024</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30782342">
<a name="30782342"></a>McCann ME, de Graaff JC, Dorris L, et al. Neurodevelopmental outcome at 5 years of age after general anaesthesia or awake-regional anaesthesia in infancy (GAS): an international, multicentre, randomised, controlled equivalence trial. <i>Lancet</i>. 2019;393(10172):664-677. doi:10.1016/S0140-6736(18)32485-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/30782342/pubmed" id="30782342" target="_blank">30782342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16023510">
<a name="16023510"></a>McIntyre J, Robertson S, Norris E, et al. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. <i>Lancet</i>. 2005;366(9481):205-210.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/16023510/pubmed" id="16023510" target="_blank">16023510</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15693964">
<a name="15693964"></a>McKenzie CA, McKinnon W, Naughton DP, et al. Differentiating midazolam over-sedation from neurological damage in the intensive care unit. <i>Crit Care</i>. 2005;9(1):R32-R36. doi:10.1186/cc3010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/15693964/pubmed" id="15693964" target="_blank">15693964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8528871">
<a name="8528871"></a>McMullin ST, Schaiff RA, and Dietzen DJ, “Stability of Midazolam Hydrochloride in Polyvinyl Chloride Bags Under Fluorescent Light,” <i>Am J Hosp Pharm</i>, 1995, 52(18), 2018-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/8528871/pubmed" id="8528871" target="_blank">8528871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19041216">
<a name="19041216"></a>Mercadante S, Intravaia G, Villari P, Ferrera P, David F, Casuccio A. Controlled sedation for refractory symptoms in dying patients. <i>J Pain Symptom Manage</i>. 2009;37(5):771-779. doi:10.1016/j.jpainsymman.2008.04.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/19041216/pubmed" id="19041216" target="_blank">19041216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32265601">
<a name="32265601"></a>Meyers RS, Thackray J, Matson KL, et al. <i>K</i>ey Potentially <i>I</i>nappropriate <i>D</i>rugs in Pediatrics: The KIDs List. <i>J Pediatr Pharmacol Ther</i>. 2020;25(3):175-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/32265601/pubmed" id="32265601" target="_blank">32265601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AmericanHealthPackaging.1">
<a name="AmericanHealthPackaging.1"></a>Midazolam hydrochloride syrup [prescribing information]. Berkely Heights, NJ: Hikma Pharmaceuticals; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lenoir.1">
<a name="Lenoir.1"></a>Midazolam in 0.8% sodium chloride single-dose vials [prescribing information]. Lenoir, NC: Exela; Janaury 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sandoz.1">
<a name="Sandoz.1"></a>Midazolam injection [product monograph]. Boucherville, Quebec, Canada: Sandoz Canada Inc; November 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WGCriticalCare.1">
<a name="WGCriticalCare.1"></a>Midazolam injection solution [prescribing information]. Paramus, NJ: WG Critical Care, LLC; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hospira.2">
<a name="Hospira.2"></a>Midazolam preservative-free single-dose vials injection [prescribing information]. Lake Forest, IL: Hospira; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FreseniusKabi.1">
<a name="FreseniusKabi.1"></a>Midazolam Simplist prefilled syringe [prescribing information]. Lake Zurich, IL: Fresenius Kabi; January 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28818854">
<a name="28818854"></a>Milési C, Baleine J, Mura T, et al. Nasal midazolam vs ketamine for neonatal intubation in the delivery room: a randomised trial. <i>Arch Dis Child Fetal Neonatal Ed</i>. 2018;103(3):F221-F226. doi:10.1136/archdischild-2017-312808<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/28818854/pubmed" id="28818854" target="_blank">28818854</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17127776">
<a name="17127776"></a>Mittal P, Manohar R, and Rawat AK, "Comparative Study of Intranasal Midazolam and Intravenous Diazepam Sedation for Procedures and Seizures,"<i> Indian J Pediatr</i>, 2006, 73(11):975-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/17127776/pubmed" id="17127776" target="_blank">17127776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Moore.1">
<a name="Moore.1"></a>Moore GP, Moore MJ. Assessment and emergency management of the acutely agitated or violent adult. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 28, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18166545">
<a name="18166545"></a>Mpimbaza A, Ndeezi G, Staedke S, et al, "Comparison of Buccal Midazolam With Rectal Diazepam in the Treatment of Prolonged Seizures in Ugandan Children: A Randomized Clinical Trial," <i>Pediatrics</i>, 2008, 121(1):58-64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/18166545/pubmed" id="18166545" target="_blank">18166545</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24910118">
<a name="24910118"></a>Mula M. The safety and tolerability of intranasal midazolam in epilepsy. <i>Expert Rev Neurother</i>. 2014;14(7):735-740. doi: 10.1586/14737175.2014.925398.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/24910118/pubmed" id="24910118" target="_blank">24910118</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12883399">
<a name="12883399"></a>Mulla H, McCormack P, Lawson G, Firmin RK, Upton DR. Pharmacokinetics of midazolam in neonates undergoing extracorporeal membrane oxygenation. <i>Anesthesiology</i>. 2003;99(2):275-282. doi:10.1097/00000542-200308000-00008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/12883399/pubmed" id="12883399" target="_blank">12883399</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25147175">
<a name="25147175"></a>Murray KL, Wright D, Laxton B, Miller KM, Meyers J, Englebright J. Implementation of standardized pediatric i.v. medication concentrations. <i>Am J Health Syst Pharm</i>. 2014;71(17):1500-1508.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/25147175/pubmed" id="25147175" target="_blank">25147175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21208198">
<a name="21208198"></a>Nakken KO, Lossius MI. Buccal midazolam or rectal diazepam for treatment of residential adult patients with serial seizures or status epilepticus. <i>Acta Neurol Scand</i>. 2011;124(2):99-103. doi:10.1111/j.1600-0404.2010.01474.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/21208198/pubmed" id="21208198" target="_blank">21208198</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nayzilam.2">
<a name="Nayzilam.2"></a>Nayzilam (midazolam) [prescribing information]. Smyrna, GA: UCB, Inc; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10519733">
<a name="10519733"></a>Nelson J, Chouinard G. Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound, and withdrawal. Canadian Society for Clinical Pharmacology. <i>Can J Clin Pharmacol</i>. 1999;6(2):69-83.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/10519733/pubmed" id="10519733" target="_blank">10519733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23470068">
<a name="23470068"></a>Neuman G, Koren G. Safety of procedural sedation in pregnancy. <i>J Obstet Gynaecol Can</i>. 2013;35(2):168-173. doi: 10.1016/S1701-2163(15)31023-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/23470068/pubmed" id="23470068" target="_blank">23470068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28141899">
<a name="28141899"></a>Ng E, Taddio A, Ohlsson A. Intravenous midazolam infusion for sedation of infants in the neonatal intensive care unit. <i>Cochrane Database Syst Rev</i>. 2017;1(1):CD002052. doi:10.1002/14651858.CD002052.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/28141899/pubmed" id="28141899" target="_blank">28141899</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35235572">
<a name="35235572"></a>Noh Y, Lee H, Choi A, et al. First-trimester exposure to benzodiazepines and risk of congenital malformations in offspring: a population-based cohort study in South Korea. <i>PLoS Med</i>. 2022;19(3):e1003945. doi:10.1371/journal.pmed.1003945<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/35235572/pubmed" id="35235572" target="_blank">35235572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28888583">
<a name="28888583"></a>Olutoye OA, Baker BW, Belfort MA, Olutoye OO. Food and Drug Administration warning on anesthesia and brain development: implications for obstetric and fetal surgery. <i>Am J Obstet Gynecol</i>. 2018;218(1):98-102.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/28888583/pubmed" id="28888583" target="_blank">28888583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29600413">
<a name="29600413"></a>Parra Palacio S, Giraldo Hoyos CE, Arias Rodríguez C, Mejía Arrieta D, Vargas Gómez JJ, Krikorian A. Palliative sedation in advanced cancer patients hospitalized in a specialized palliative care unit. <i>Support Care Cancer</i>. 2018;26(9):3173-3180. doi:10.1007/s00520-018-4164-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/29600413/pubmed" id="29600413" target="_blank">29600413</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22016443">
<a name="22016443"></a>Patel SB, Kress JP. Sedation and analgesia in the mechanically ventilated patient. <i>Am J Respir Crit Care Med</i>. 2012;185(5):486-497. doi:10.1164/rccm.201102-0273CI<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/22016443/pubmed" id="22016443" target="_blank">22016443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22058104">
<a name="22058104"></a>Phillips MS, “Standardizing I.V. Infusion Concentrations: National Survey Results,” <i>Am J Health Syst Pharm</i>, 2011, 68(22):2176-82.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/22058104/pubmed" id="22058104" target="_blank">22058104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8045143">
<a name="8045143"></a>Pohlman AS, Simpson KP, Hall JB. Continuous intravenous infusions of lorazepam versus midazolam for sedation during mechanical ventilatory support: a prospective, randomized study. <i>Crit Care Med</i>. 1994;22(8):1241-1247. doi:10.1097/00003246-199408000-00007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/8045143/pubmed" id="8045143" target="_blank">8045143</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29301574">
<a name="29301574"></a>Prado BL, Gomes DBD, Usón Júnior PLS, et al. Continuous palliative sedation for patients with advanced cancer at a tertiary care cancer center. <i>BMC Palliat Care</i>. 2018;17(1):13. doi:10.1186/s12904-017-0264-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/29301574/pubmed" id="29301574" target="_blank">29301574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11442156">
<a name="11442156"></a>Prasad A, Worrall BB, Bertram EH, Bleck TP. Propofol and midazolam in the treatment of refractory status epilepticus. <i>Epilepsia</i>. 2001;42(3):380-386. doi:10.1046/j.1528-1157.2001.27500.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/11442156/pubmed" id="11442156" target="_blank">11442156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28259732">
<a name="28259732"></a>Radojčić MR, El Marroun H, Miljković B, et al. Prenatal exposure to anxiolytic and hypnotic medication in relation to behavioral problems in childhood: a population-based cohort study. <i>Neurotoxicol Teratol</i>. 2017;61:58-65. doi:10.1016/j.ntt.2017.02.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/28259732/pubmed" id="28259732" target="_blank">28259732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31303443">
<a name="31303443"></a>Rajiv KR, Radhakrishnan A. Status epilepticus in pregnancy - can we frame a uniform treatment protocol? <i>Epilepsy Behav</i>. 2019;101(pt B):106376. doi:10.1016/j.yebeh.2019.06.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/31303443/pubmed" id="31303443" target="_blank">31303443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28366351">
<a name="28366351"></a>Rech MA, Barbas B, Chaney W, Greenhalgh E, Turck C. When to pick the nose: out-of-hospital and emergency department intranasal administration of medications. <i>Ann Emerg Med</i>. 2017;70(2):203-211. doi:10.1016/j.annemergmed.2017.02.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/28366351/pubmed" id="28366351" target="_blank">28366351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29624435">
<a name="29624435"></a>Reece-Stremtan S, Campos M, Kokajko L; Academy of Breastfeeding Medicine. ABM clinical protocol #15: analgesia and anesthesia for the breastfeeding mother, revised 2017. <i>Breastfeed Med</i>. 2017;12(9):500-506.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/29624435/pubmed" id="29624435" target="_blank">29624435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Roberts.2019">
<a name="Roberts.2019"></a>Roberts J. <i>Roberts and Hedges’ Clinical Procedures in Emergency Medicine and Acute Care</i>. 7th ed. Elsevier; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rosero.1">
<a name="Rosero.1"></a>Rosero EB. Monitored anesthesia care in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 14, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29143367">
<a name="29143367"></a>Saarelainen L, Tolppanen AM, Koponen M, et al. Risk of death associated with new benzodiazepine use among persons with Alzheimer disease: A matched cohort study. <i>Int J Geriatr Psychiatry.</i> 2018;33(4):583-590. doi: 10.1002/gps.4821.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/29143367/pubmed" id="29143367" target="_blank">29143367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sansevere.1">
<a name="Sansevere.1"></a>Sansevere AJ, Bergin AM. Neonatal seizures. In: Eichenwald EC, Hansen AR, Martin CR, Stark AR. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 9th ed. Lippincott Williams &amp; Wilkins; 2022:chap. 56.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985999">
<a name="10985999"></a>Scheepers M, Scheepers B, Clarke M, Comish S, Ibitoye M. Is intranasal midazolam an effective rescue medication in adolescents and adults with severe epilepsy? <i>Seizure</i>. 2000;9(6):417-422. doi:10.1053/seiz.2000.0425<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/10985999/pubmed" id="10985999" target="_blank">10985999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Seizalam.1">
<a name="Seizalam.1"></a>Seizalam injection (midazolam) [prescribing information]. Columbia, MD: Meridian Medical Technologies Inc; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24565384">
<a name="24565384"></a>Senel AC, Mergan F. Premedication with midazolam prior to caesarean section has no neonatal adverse effects. <i>Braz J Anesthesiol</i>. 2014;64(1):16-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/24565384/pubmed" id="24565384" target="_blank">24565384</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs used to treat pediatric emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450. doi:10.1542/peds.2019-3450<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22579258">
<a name="22579258"></a>Shergill AK, Ben-Menachem T, Chandrasekhara V, et al. Guidelines for endoscopy in pregnant and lactating women. <i>Gastrointest Endosc</i>. 2012;76(1):18-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/22579258/pubmed" id="22579258" target="_blank">22579258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22335736">
<a name="22335736"></a>Silbergleit R, Durkalski V, Lowenstein D, et al; NETT Investigators. Intramuscular versus intravenous therapy for prehospital status epilepticus. <i>N Engl J Med</i>. 2012;366(7):591-600. doi:10.1056/NEJMoa1107494<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/22335736/pubmed" id="22335736" target="_blank">22335736</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28435493">
<a name="28435493"></a>Silverman EC, Sporer KA, Lemieux JM, et al. Prehospital care for the adult and pediatric seizure patient: current evidence-based recommendations. <i>West J Emerg Med</i>. 2017;18(3):419-436. doi:10.5811/westjem.2016.12.32066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/28435493/pubmed" id="28435493" target="_blank">28435493</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sinclair-Pingel.1">
<a name="Sinclair-Pingel.1"></a>Sinclair-Pingel J, Grisso AG, Hargrove FR, Wright L. Implementation of standardized concentrations for continuous infusions using a computerized provider Order Entry System [published correction appears in <i>Hosp Pharm</i>. 2007; 42:84-85]. <i>Hosp Pharm</i>. 2006;41:1102-1106.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6116606">
<a name="6116606"></a>Smith MT, Eadie MJ, and Brophy TO, “The Pharmacokinetics of Midazolam in Man,” <i>Eur J Clin Pharmaocl</i>, 1981, 19(4):271-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/6116606/pubmed" id="6116606" target="_blank">6116606</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35231912">
<a name="35231912"></a>Snyers D, Tribolet S, Rigo V. Intranasal analgosedation for infants in the neonatal intensive care unit: a systematic review. <i>Neonatology</i>. 2022;119(3):273-284. doi:10.1159/000521949<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/35231912/pubmed" id="35231912" target="_blank">35231912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17316150">
<a name="17316150"></a>Spina SP, Ensom MHH. Clinical pharmacokinetic monitoring of midazolam in critically ill patients. <i>Pharmacotherapy.</i> 2007;27(3):389-398. doi:10.1592/phco.27.3.389<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/17316150/pubmed" id="17316150" target="_blank">17316150</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spruill.1">
<a name="Spruill.1"></a>Spruill CT, LaBrecque MA. Preventing and treating pain and stress among infants in the newborn intensive care unit. In: Eichenwald EC, Hansen AR, Martin CR, Stark AR, eds. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 9th ed. Lippincott Williams &amp; Wilkins; 2022: chap. 70.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24259635">
<a name="24259635"></a>Stollings JL, Diedrich DA, Oyen LJ, Brown DR. Rapid-sequence intubation: a review of the process and considerations when choosing medications. <i>Ann Pharmacother</i>. 2014;48(1):62-76. doi:10.1177/1060028013510488<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/24259635/pubmed" id="24259635" target="_blank">24259635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27798767">
<a name="27798767"></a>Strøm C, Rasmussen LS, Steinmetz J. Practical management of anaesthesia in the elderly. <i>Drugs Aging.</i> 2016;33(11):765-777.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/27798767/pubmed" id="27798767" target="_blank">27798767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27272582">
<a name="27272582"></a>Sun LS, Li G, Miller TL, et al. Association between a single general anesthesia exposure before age 36 months and neurocognitive outcomes in later childhood. <i>JAMA</i>. 2016;315(21):2312-2320. doi:10.1001/jama.2016.6967<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/27272582/pubmed" id="27272582" target="_blank">27272582</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36520439">
<a name="36520439"></a>Sundbakk LM, Gran JM, Wood ME, et al. Association of prenatal exposure to benzodiazepines and z-hypnotics with risk of attention-deficit/hyperactivity disorder in childhood. <i>JAMA Netw Open</i>. 2022;5(12):e2246889. doi:10.1001/jamanetworkopen.2022.46889<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/36520439/pubmed" id="36520439" target="_blank">36520439</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15685515">
<a name="15685515"></a>Swart EL, de Jongh J, Zuideveld KP, et al. Population pharmacokinetics of lorazepam and midazolam and their metabolites in intensive care patients on continuous venovenous hemofiltration. <i>Am J Kidney Dis.</i> 2005;45(2):360-371. doi:10.1053/j.ajkd.2004.09.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/15685515/pubmed" id="15685515" target="_blank">15685515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35909254">
<a name="35909254"></a>Szpunar MJ, Freeman MP, Kobylski LA, et al. Risk of major malformations in infants after first-trimester exposure to benzodiazepines: results from the Massachusetts General Hospital National Pregnancy Registry for Psychiatric Medications. <i>Depress Anxiety</i>. 2022;39(12):751-759. doi:10.1002/da.23280<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/35909254/pubmed" id="35909254" target="_blank">35909254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19114297">
<a name="19114297"></a>Talukdar B and Chakrabarty B, "Efficacy of Buccal Midazolam Compared to Intravenous Diazepam in Controlling Convulsions in Children: A Randomized Controlled Trial,"<i> Brain Dev</i>, 2009, 31(10):744-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/19114297/pubmed" id="19114297" target="_blank">19114297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11046209">
<a name="11046209"></a>Tanaka M, Sato M, Saito A, Nishikawa T. Reevaluation of rectal ketamine premedication in children: comparison with rectal midazolam. <i>Anesthesiology</i>. 2000;93(5):1217-1224.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/11046209/pubmed" id="11046209" target="_blank">11046209</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Thornton.2020">
<a name="Thornton.2020"></a>Thornton K, Savel RH. Intensive care unit management of patients with obesity. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 25, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tietze.2020">
<a name="Tietze.2020"></a>Tietze KJ, Fuchs B. Sedative-analgesic medications in critically ill adults: Properties, dose regimens, and adverse effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 24, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30891943">
<a name="30891943"></a>Tinker SC, Reefhuis J, Bitsko RH, et al; National Birth Defects Prevention Study. Use of benzodiazepine medications during pregnancy and potential risk for birth defects, National Birth Defects Prevention Study, 1997-2011. <i>Birth Defects Res</i>. 2019;111(10):613-620. doi:10.1002/bdr2.1497<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/30891943/pubmed" id="30891943" target="_blank">30891943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10890677">
<a name="10890677"></a>Tobias JD. Tolerance, withdrawal, and physical dependency after long-term sedation and analgesia of children in the pediatric intensive care unit. <i>Crit Care Med</i>. 2000;28(6):2122-2132. doi:10.1097/00003246-200006000-00079<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/10890677/pubmed" id="10890677" target="_blank">10890677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14512476">
<a name="14512476"></a>TREC Collaborative Group. Rapid tranquillisation for agitated patients in emergency psychiatric rooms: a randomised trial of midazolam versus haloperidol plus promethazine. <i>BMJ</i>. 2003;327(7417):708-713. doi:10.1136/bmj.327.7417.708<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/14512476/pubmed" id="14512476" target="_blank">14512476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16164495">
<a name="16164495"></a>Treluyer JM, Zohar S, Rey E, et al, "Minimum Effective Dose of Midazolam for Sedation of Mechanically Ventilated Neonates," <i>J Clin Pharm Ther</i>, 2005, 30(5):479-85.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/16164495/pubmed" id="16164495" target="_blank">16164495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3395535">
<a name="3395535"></a>Trouvin J H, Farinotti R, Haberer JP, Servin F, Chauvin M, Duvaldestin P. Pharmacokinetics of midazolam in anaesthetized cirrhotic patients. <i>Br J Anaesth.</i> 1988;60(7):762-767. doi:10.1093/bja/60.7.762<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/3395535/pubmed" id="3395535" target="_blank">3395535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12536286">
<a name="12536286"></a>Ulvi H, Yoldas T, Mungen B, Yigiter R. Continuous infusion of midazolam in the treatment of refractory generalized convulsive status epilepticus. <i>Neurol Sci</i>. 2002;23(4):177-182. doi:10.1007/s100720200058<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/12536286/pubmed" id="12536286" target="_blank">12536286</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VA-DoD.1">
<a name="VA-DoD.1"></a>US Department of Veterans Affairs/Department of Defense (VA/DoD). VA/DoD clinical practice guideline for the management of substance use disorders. <a href="https://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPGRevised22216.pdf" target="_blank">https://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPGRevised22216.pdf</a>. Updated January 2015. Accessed May 16, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>US Food and Drug Administration. FDA Drug Safety Communication: FDA review results in new warnings about using general anesthetics and sedation drugs in young children and pregnant women. <a href="https://www.fda.gov/Drugs/DrugSafety/ucm554634.htm" target="_blank">https://www.fda.gov/Drugs/DrugSafety/ucm554634.htm</a>. Updated April 27, 2017. Accessed May 26, 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12172357">
<a name="12172357"></a>Uygur-Bayramiçli O, Dabak R, Kuzucuoglu T, Kavakli B. Sedation with intranasal midazolam in adults undergoing upper gastrointestinal endoscopy. <i>J Clin Gastroenterol</i>. 2002;35(2):133-137. doi:10.1097/00004836-200208000-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/12172357/pubmed" id="12172357" target="_blank">12172357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25572061">
<a name="25572061"></a>van den Broek MP, van Straaten HL, Huitema AD, et al. Anticonvulsant effectiveness and hemodynamic safety of midazolam in full-term infants treated with hypothermia. <i>Neonatology</i>. 2015;107(2):150-156. doi:10.1159/000368180<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/25572061/pubmed" id="25572061" target="_blank">25572061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29570859">
<a name="29570859"></a>van der Vossen AC, van Nuland M, Ista EG, de Wildt SN, Hanff LM. Oral lorazepam can be substituted for intravenous midazolam when weaning paediatric intensive care patients off sedation. <i>Acta Paediatr</i>. 2018;107(9):1594-1600. doi:10.1111/apa.14327<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/29570859/pubmed" id="29570859" target="_blank">29570859</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VON.1">
<a name="VON.1"></a>Vermont Oxford Network (VON). Neonatal drug concentrations. https://public.vtoxford.org/wp-content/uploads/2022/11/Neonatal-Drug-Concentrations-Updated-November-2022.pdf. Updated November 2022. Accessed July 19, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22536226">
<a name="22536226"></a>Vinkers CH, Olivier B. Mechanisms underlying tolerance after long-term benzodiazepine use: a future for subtype-selective gaba(a) receptor modulators? <i>Adv Pharmacol Sci</i>. 2012;2012:1-19.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/22536226/pubmed" id="22536226" target="_blank">22536226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35367514">
<a name="35367514"></a>Wang X, Zhang T, Ekheden I, et al. Prenatal exposure to benzodiazepines and Z-drugs in humans and risk of adverse neurodevelopmental outcomes in offspring: a systematic review. <i>Neurosci Biobehav Rev</i>. 2022;137:104647. doi:10.1016/j.neubiorev.2022.104647<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/35367514/pubmed" id="35367514" target="_blank">35367514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14528201">
<a name="14528201"></a>Waring JP, Baron TH, Hirota WK, et al; American Society for Gastrointestinal Endoscopy, Standards of Practice Committee. Guidelines for conscious sedation and monitoring during gastrointestinal endoscopy. <i>Gastrointest Endosc</i>. 2003;58(3):317-322. doi:10.1067/s0016-5107(03)00001-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/14528201/pubmed" id="14528201" target="_blank">14528201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30080777">
<a name="30080777"></a>Warrington SE, Collier HK, Himebauch AS, Wolfe HA. Evaluation of IV to enteral benzodiazepine conversion calculations in a pediatric intensive care setting. <i>Pediatr Crit Care Med</i>. 2018;19(11):e569-e575. doi:10.1097/PCC.0000000000001687<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/30080777/pubmed" id="30080777" target="_blank">30080777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17894421">
<a name="17894421"></a>Wikner BN, Stiller CO, Bergman U, et al. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. <i>Pharmacoepidemiol Drug Saf</i>. 2007;16(11):1203-1210.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/17894421/pubmed" id="17894421" target="_blank">17894421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3688386">
<a name="3688386"></a>Wilson CM, Dundee JW, Moore J, Howard PJ, Collier PS. A comparison of the early pharmacokinetics of midazolam in pregnant and nonpregnant women. <i>Anaesthesia</i>. 1987;42(10):1057-1062.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/3688386/pubmed" id="3688386" target="_blank">3688386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28297728">
<a name="28297728"></a>Wodarz N, Krampe-Scheidler A, Christ M, et al. Evidence-based guidelines for the pharmacological management of acute methamphetamine-related disorders and toxicity. <i>Pharmacopsychiatry</i>. 2017;50(3):87-95. doi:10.1055/s-0042-123752<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/28297728/pubmed" id="28297728" target="_blank">28297728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30981104">
<a name="30981104"></a>Zaporowska-Stachowiak I, Szymański K, Oduah MT, Stachowiak-Szymczak K, Łuczak J, Sopata M. Midazolam: safety of use in palliative care: a systematic critical review. <i>Biomed Pharmacother</i>. 2019;114:108838. doi:10.1016/j.biopha.2019.108838<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/30981104/pubmed" id="30981104" target="_blank">30981104</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9650 Version 598.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
